<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>2021-ICPi-Summary-of-Recs-Table</title><link href="2021-ICPi-Summary-of-Recs-Table_files/navigation.css" rel="stylesheet" type="text/css"/><link href="2021-ICPi-Summary-of-Recs-Table_files/document.css" rel="stylesheet" type="text/css"/><meta name="author" content="Kaitlin Einhaus"/></head><body><p class="top_nav"><a href="2021-ICPi-Summary-of-Recs-Table_files/part1.htm">Next &gt;</a></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="391" height="42" alt="image" src="2021-ICPi-Summary-of-Recs-Table_files/Image_001.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:27pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4" bgcolor="#002456"><p class="s1" style="text-indent: 0pt;text-align: center;">Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy:</p><p class="s1" style="text-indent: 0pt;line-height: 12pt;text-align: center;">ASCO Guideline Update</p></td></tr><tr style="height:22pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Site</p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse Event</p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Page</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="3"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">1.0. <span class="s3">Cutaneous Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1.1. <span class="s3">Rash or Inflammatory Dermatitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1.2. <span class="s3">Bullous Dermatoses</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1.3. <span class="s3">Severe Cutaneous Adverse Reactions</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.0. <span class="s3">Gastrointestinal Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2.1. <span class="s3">Colitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2.2. <span class="s3">Hepatitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.0. <span class="s3">Lung Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.1. <span class="s3">Pneumonitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="5"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. <span class="s3">Endocrine Toxicities</span></p></td><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.1. <span class="s3">Thyroid</span></p></td><td style="width:392pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.1.1. <span class="s3">Primary Hypothyroidism</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12</p></td></tr><tr style="height:12pt"><td style="width:392pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.1.2. <span class="s3">Thyrotoxicosis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">13</p></td></tr><tr style="height:12pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.2. <span class="s3">Adrenal</span></p></td><td style="width:392pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.2.1. <span class="s3">Primary Adrenal Insufficiency</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">13</p></td></tr><tr style="height:12pt"><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.3. <span class="s3">Pituitary</span></p></td><td style="width:392pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.3.1. <span class="s3">Hypophysitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">15</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.4. <span class="s3">Diabetes</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">16</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="3"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">5.0. <span class="s3">Musculoskeletal Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5.1. <span class="s3">Inflammatory Arthritis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">19</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5.2. <span class="s3">Myositis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5.3. <span class="s3">Polymyalgia-like Syndrome</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">22</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.0. <span class="s3">Renal Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6.1. <span class="s3">Nephritis or Acute Kidney Injury</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6.2. <span class="s3">Nephritis or Acute Kidney Injury Follow-Up</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">24</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="7"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. <span class="s3">Nervous System Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.1. <span class="s3">Myasthenia Gravis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">25</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.2. <span class="s3">Guillain-Barre Syndrome</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">26</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.3. <span class="s3">Peripheral Neuropathy</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">27</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.4. <span class="s3">Autonomic Neuropathy</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">27</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.5. <span class="s3">Aseptic Meningitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">28</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.6. <span class="s3">Encephalitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">29</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.7. <span class="s3">Demyelinating Diseases</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">29</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="7"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. <span class="s3">Hematologic Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.1. <span class="s3">Hemolytic Anemia</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">31</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.2. <span class="s3">Acquired Thrombotic Thrombocytopenic Purpura</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">32</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.3. <span class="s3">Hemolytic Uremic Syndrome</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">33</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.4. <span class="s3">Aplastic Anemia</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">34</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.5. <span class="s3">Lymphopenia</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">34</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.6. <span class="s3">Immune Thrombocytopenia</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">35</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.7. <span class="s3">Acquired Hemophilia A</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">36</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.0. <span class="s3">Cardiovascular Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9.1. <span class="s3">Myocarditis, Pericarditis, Arrythmias, Impaired Ventricular Function with Heart Failure and Vasculitis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">37</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9.2. <span class="s3">Venous Thromboembolism</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">38</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:27pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3" bgcolor="#002456"><p class="s1" style="text-indent: 0pt;text-align: center;">Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy:</p><p class="s1" style="text-indent: 0pt;line-height: 12pt;text-align: center;">ASCO Guideline Update</p></td></tr><tr style="height:22pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Site</p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Adverse Event</p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D5E0ED"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Page</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.0. <span class="s3">Ocular Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.1. <span class="s3">Uveitis or Iritis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">40</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.2. <span class="s3">Episcleritis</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">41</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11.0. <span class="s3">Systemic Toxicities</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11.1. <span class="s3">Infusion-Related Reactions</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">42</p></td></tr><tr style="height:12pt"><td style="width:153pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="4"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">12.0. <span class="s3">Steroid Use</span></p></td><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12.1. <span class="s3">Pretreatment Considerations</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">43</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12.2. <span class="s3">Prevention of Opportunistic Infections</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">43</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12.3. <span class="s3">Monitoring for Acute or Short-Term and Long-Term Adverse Effects</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">43</p></td></tr><tr style="height:12pt"><td style="width:486pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12.4. <span class="s3">Tapering of Steroids</span></p></td><td style="width:81pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.0. Cutaneous Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.1.Rash or Inflammatory Dermatitis</p></td></tr><tr style="height:124pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Pertinent history and physical exam including examination of the oral mucosa, assessment for blister formation, assessment of body surface area involved.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Review full list of patient medications to rule out other drug-induced cause for photosensitivity.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Rule out any other etiology of the skin problem, such as an infection, an effect of another drug, including prior or other recent cancer therapies, or a skin condition linked to another systemic disease or unrelated primary skin disorder.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Recent or new complete blood count and comprehensive metabolic panel (if needed for skin differential diagnosis).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider referral to dermatologist if autoimmune skin disease is suspected.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider skin biopsy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider clinical monitoring with use of serial clinical photography.</span></p></td></tr><tr style="height:72pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p><p class="s3" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Grading according to CTCAE criteria is a challenge for skin. Instead, severity may be based on body surface area (BSA), tolerability, morbidity, and duration.</p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:38pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G1: <span class="s3">Rash covering &lt;10% BSA, which may or may not be associated with symptoms of pruritus or tenderness.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Treat with topical emollients and/or mild-moderate potency topical corticosteroids.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Counsel patients to avoid skin irritants.</span></p></td></tr><tr style="height:74pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G2: <span class="s3">Rash covering 10 - 30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental activities of daily living (ADL); rash covering &gt; 30% BSA with or without mild symptoms.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi and monitor weekly for improvement. If skin toxicity not improved after 4 weeks, then re- grade toxicity as grade 3.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">In addition, treat with topical emollients, oral antihistamines, and medium-to-high potency topical corticosteroids.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider initiating prednisone (or equivalent) at dosing 0.5-1 mg/kg, tapering over 4 weeks. In patients with pruritis without rash, consider topical anti-itch remedies (e.g. refrigerated menthol, pramoxine).</span></p></td></tr><tr style="height:87pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Rash covering &gt;30% BSA with moderate or severe symptoms; limiting self-care ADL.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi therapy and consult with dermatology to determine appropriateness of resuming.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Treat with topical emollients, oral antihistamines, and high-potency topical corticosteroids. May also consider phototherapy to treat severe pruritus.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate oral prednisone or equivalent (1 mg/kg/d) tapering over at least 4 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Once downgraded to ≤G1 and prednisone (or equivalent) below 10mg/d, clinicians may consider resuming ICPi</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">therapy with close monitoring and follow-up with dermatology in certain cases such as psoriasis.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">In patients with pruritis without rash, may treat with gabapentin, pregabalin, aprepitant, or dupilumab.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.0. Cutaneous Toxicities</p></td></tr><tr style="height:99pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Severe consequences requiring hospitalization or urgent intervention indicated or life-threatening consequences.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Immediate hold ICPi</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May admit patient immediately with direct oncology involvement and with an urgent consult by dermatology.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Systemic steroids: IV methylprednisolone (or equivalent) dosed at 1-2mg/kg with slow tapering when the toxicity resolves.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor closely for progression to Severe Cutaneous Adverse Reaction (SCAR).</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider alternative antineoplastic therapy over resuming ICPis if the skin irAE does not resolve to ≤G1. If ICPis are the patient’s only option, consider restarting once these side effects have resolved to a G1 level with close dermatology follow-up.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.2.Bullous Dermatoses</p></td></tr><tr style="height:147pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: justify;"><span class="s6">  </span><span class="s3">Physical exam.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: justify;"><span class="s6">  </span><span class="s3">Rule out any other etiology of the skin problem, such as an infection, an effect of another drug, or a skin condition linked to another systemic disease.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: justify;"><span class="s6">  </span><span class="s3">Dermatology consultation for consideration of skin biopsy and direct immunofluorescence. Further serologic work-up, such as ELISA testing or indirect immunofluorescence may be pursued.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: justify;"><span class="s6">  </span><span class="s3">Primer on monitoring for complicated cutaneous adverse drug reactions:</span></p><p class="s7" style="padding-left: 77pt;padding-right: 11pt;text-indent: -18pt;text-align: justify;">o <span class="s3">Review of systems: Skin pain (“like a sunburn”), fevers, malaise, myalgias, arthralgias, abdominal pain, ocular discomfort or photophobia, sores or discomfort in the nares, sores or discomfort in the oropharynx, odynophagia, hoarseness, dysuria, sores or discomfort in the vaginal area for women or involving the meatus of the penis for men, sores in the perianal area or pain with bowel movements.</span></p><p class="s7" style="padding-left: 77pt;padding-right: 10pt;text-indent: -18pt;text-align: justify;">o <span class="s3">Physical exam: Include vital signs and a full skin exam specifically evaluating all skin surfaces and mucous membranes (eyes, nares, oropharynx, genitals, and perianal area). Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of DIHS/DRESS (see 1.3</span></p><p class="s3" style="padding-left: 77pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Section). Assess for pustules or blisters or erosions in addition to areas of “dusky erythema” which may feel painful to palpation.</p></td></tr><tr style="height:23pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:62pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic or blisters covering &lt;10% BSA and no associated erythema</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If blisters are &lt;10% BSA, are asymptomatic and non-inflammatory (such as the case with friction blisters or pressure blisters), cessation of ICPi is not necessary and only observation/local wound care is warranted.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">When symptomatic bullae or erosions, which are “deroofed” vesicles or bullae, are noted on the skin or mucosal</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">surfaces, the cutaneous irAE is considered at least grade 2.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">See grade 2 management recommendations.</span></p></td></tr><tr style="height:135pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Blistering that affects quality of life and require intervention based on diagnosis not meeting criteria for &gt; grade 2. Blisters covering 10%-30% BSA.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi therapy and consult with dermatology for steroid-sparing options, work up, and to determine appropriateness of resuming.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Attention given to general local wound care, which includes plain petrolatum ointment and bandages or plain petrolatum ointment gauze and bandage over any open erosions, which are left on the skin after the blister has “popped” or if the roof of the blister easily sloughs off.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate class 1 high potency topical steroid, e.g. clobetasol, betamethasone, or equivalent and reassess every 3 days for progression or improvement.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Low threshold to initiate treatment with prednisone (or equivalent) at 0.5-1 mg/kg/d dosing and taper over at least 4 weeks.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor patients closely for progression to greater body surface area involvement and/or mucous membrane involvement. Consider following patients closely using serial photography.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.0. Cutaneous Toxicities</p></td></tr><tr style="height:75pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Skin sloughing covering &gt;30% BSA with associated pain and limiting self-care ADL.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi therapy and consider admitting patient.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer IV methylprednisolone (or equivalent) 1-2 mg/kg and when appropriate convert to oral steroids, tapering over at least 4 weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If bullous pemphigoid is diagnosed, it may be possible to avoid long-term use of systemic steroids and transition to steroid-sparing options (e.g IVIG and rituximab), as an alternative approach to treating the irAE.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s6">  </span><span class="s3">Consult with dermatology to determine appropriateness of resuming ICPi once symptoms improve.</span></p></td></tr><tr style="height:75pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Blisters covering &gt;30% BSA with associated fluid or electrolyte abnormalities.</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient immediately and place under supervision of a dermatologist.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer IV methylprednisolone (or equivalent) 1–2mg/kg and when appropriate convert to oral steroids, with tapering over at least 4 weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 4pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If bullous pemphigoid is diagnosed, it may be possible to avoid long-term use of systemic steroids and treat with steroid-sparing options, as an alternative approach to treating the irAE (e.g IVIG and rituximab).</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.3.Severe Cutaneous Adverse Reactions (SCAR)</p></td></tr><tr style="height:124pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Total body skin exam with attention to examining ALL mucous membranes, as well as complete review of systems.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Rule out any other etiology of the skin problem, such as an infection, an effect of another drug or a skin condition linked to another systemic disease.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">A biological checkup including a CBC with DIFF, liver and kidney function tests; consider UA in the context of DRESS to assess for associated nephritis in addition to the blood work. If the patient is febrile, blood cultures should be considered, as well. Skin biopsies to assess for full thickness epidermal necrosis, as is seen in SJS or TEN, as well as other possible etiologies like paraneoplastic pemphigus or other autoimmune blistering dermatoses or other drug reactions, such as AGEP.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow patients closely using serial clinical photography.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If mucous membrane involvement or blistering is noted on the skin, consider early admission to a burn center for further monitoring and management.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow primer on monitoring for complicated cutaneous adverse drug reactions from section 1.2.</span></p></td></tr><tr style="height:24pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">In cases of suspected SJS or any mucous membrane involvement (not including isolated stomatitis), discontinue ICPi</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">treatment and consult dermatology. Monitor closely for improvement regardless of grade.</p></td></tr><tr style="height:24pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G1 and G2: <span class="s3">N/A</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">For the SCAR adverse reactions, there are no grade 1 or 2 categories. If limited body surface area is involved with bullae</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">or erosions, there should remain high concern that this reaction will progress to grade 3 or 4.</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">1.0. Cutaneous Toxicities</p></td></tr><tr style="height:172pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 8pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Skin sloughing covering &lt;10% BSA with mucosal involvement associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment).</span></p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi therapy and consult with dermatology.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Admit to burn unit and/or consult wound services with attention to supportive care including fluid and electrolyte balance, minimizing insensible water losses, and preventing infection.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Treat skin with topical emollients and other petrolatum emollients, oral antihistamines, and high strength topical corticosteroids. Dimethicone may also be offered as an alternative to petrolatum.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer IV methylprednisolone (or equivalent) 0.5 -1 mg/kg and convert to oral corticosteroids on response, wean over at least 4 weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Given the immune mechanism of action of these medicines, use of immune suppression is warranted and should be offered. The usual prohibition of corticosteroids for SJS is not relevant here, as the underlying mechanism is a T-cell immune-directed toxicity. Adequate suppression is necessary with corticosteroids or other agents and may be prolonged in cases of DRESS or drug hypersensitivity syndrome.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">For mucous membrane involvement of SJS or TEN, appropriate consulting services should be offered to guide management in preventing sequelae from scarring (e.g. ophthalmology, otolaryngology, urology, or gynecology, as appropriate).</span></p></td></tr><tr style="height:121pt"><td style="width:175pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Skin erythema and blistering/sloughing covering ≥10% BSA with associated signs (e.g., erythema, purpura, epidermal detachment, mucous membrane detachment) and/or systemic symptoms and concerning associated blood work abnormalities (e.g., liver function test elevations in</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">the setting of DRESS or DIHS).</p></td><td style="width:545pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 5pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient immediately to a burn unit or ICU with consulted dermatology and wound care services. Consider further consultations based on management of mucosal surfaces (e.g. ophthalmology, urology, gynecology, otolaryngology, etc.).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate IV methylprednisolone (or equivalent) 1-2 mg/kg, tapering when toxicity resolves to normal.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">IVIG or cyclosporine may also be considered in severe or steroid-unresponsive cases.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider pain/palliative consultation and/or admission in patients presenting with DRESS manifestations.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.0. Gastrointestinal Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.1. Colitis</p></td></tr><tr style="height:233pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2:</p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Work up of blood (CBC, CMP, TSH), stool (culture, <i>C. diff</i>, parasite, CMV or other viral etiology, O&amp;P if appropriate), should be performed for the initial presentation, and also considered for immunosuppressant refractory cases.</p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider testing for fecal lactoferrin (for patient stratification to determine who needs more urgent endoscopy) and calprotectin (to follow up on disease activity).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Screening labs (HIV, hepatitis A and B, and TB testing), repeated annually in patients who require biologic treatment e.g. infliximab or vedolizumab for</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">&gt;1 year until treatment is completed.</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider reviewing concomitant medications that could alter the gut microbiome and their indications for prolonged use (e.g. proton pump inhibitors, antibiotics, and probiotics).</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Imaging, e.g., CT scan of abdomen and pelvis for colitis-related symptoms (abdominal pain, bleeding) to rule out colitis-related complications, including typhlitis and bowel perforation/abscess.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>GI endoscopy/colonoscopy with biopsy for patients who have positive stool inflammatory markers or colitis-related symptoms should be considered as there is evidence showing the presence of ulceration in the colon can predict steroid refractory course,<span class="s9">1 </span>which may require early infliximab.</p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Repeat colonoscopy may be considered for cases grade ≥ 2 for disease activity monitoring to document complete remission, especially if there is a plan to resume ICPi. Mucosal healing on repeat endoscopy and/or fecal calprotectin level ≤ 116µg/g can be considered the treatment target to guide decisions on when to stop biologic treatment and when to resume ICPi therapy.</span><span class="s9">1-3</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G3-4:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Complete all recommendations as above and consider inpatient care.</span></p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading <span class="s3">(based on CTCAE for diarrhea,</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">as most often used clinically)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:74pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">All Patients</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Counsel all patients to be aware of and inform their healthcare provider immediately if they experience:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">abdominal pain, nausea, cramping, blood or mucus in stool, or changes in bowel habits.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">fever, abdominal distention, constipation.</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">For grade ≥ 2, consider permanently discontinuing CTLA-4 agents and may restart PD-1, PD-L1 agents if patients recover to ≤ G1; concurrent immunosuppressant maintenance therapy should be considered only if clinically indicated in individual cases.</p></td></tr><tr style="height:99pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Increase of &lt; 4 stools per day over baseline; mild increase in ostomy output compared to baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi. Alternatively, ICPi may be held temporarily and resumed if toxicity does not exceed G1 or resolves.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">May also include supportive care with medications such as loperamide if infection has been ruled out in patients with diarrhea only and not colitis-related symptoms as a temporary measure.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor for dehydration and recommend dietary changes.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Patient should be closely monitored by phone or electronic medical system for symptoms changes by clinical providers every 3 days or more frequently if needed until stabilized.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s6">  </span><span class="s3">May obtain gastroenterology consult for prolonged G1 cases and consider endoscopy with biopsies.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.0. Gastrointestinal Toxicities</p></td></tr><tr style="height:245pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi at least until recovery to G1 – see last bullets.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">May also include supportive care with medications such as loperamide if infection has been ruled out in patients with diarrhea only and not colitis-related symptoms as a temporary measure.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider consult with gastroenterology for ≥G2.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;text-align: justify;"><span class="s6">  </span><span class="s3">Administer corticosteroids, unless diarrhea is transient, starting with initial dose of 1 mg/kg/d prednisone or equivalent until symptoms improve to G1, and then start taper over 4-6 weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;text-align: justify;"><span class="s6">  </span><span class="s3">Consider adding narrower-spectrum/more potent agents, including anti-tumor necrosis factor (infliximab) or anti-integrin (vedolizumab) antibody to patients whose colitis is corticosteroid-refractory (i.e. no decrease by one grade in 72 hours) or dependent or with high-risk endoscopic features* on initial endoscopy exam.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 31pt;text-indent: -18pt;text-align: justify;"><span class="s6">  </span><span class="s3">When symptoms improve to ≤ G1, taper corticosteroids over 4-6 weeks; may consider shorter tapers in patients also treated with biologics.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: justify;"><span class="s6">  </span><span class="s3">Endoscopic evaluation with EGD/colonoscopy is highly recommended for cases grade ≥ 2 to stratify</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: justify;">patients for early treatment of biologics based on the endoscopic findings.</p><p class="s3" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Resuming ICPi after symptoms improve to <u>&lt;</u>G1 may be considered when steroid taper is completed, risk/benefits reviewed if maintained on biologics, and/or if endoscopic and histologic remission are achieved. Fecal calprotectin <u>&lt;</u>116 μg/g may be considered as a surrogate for endoscopic and histologic remission.<span class="s9">3</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Resuming PD-1/PD-L1 agent is associated with lower risk of flare-up, however, CTLA-4 inhibitor can still be considered in selected cases, such as in patients who have not yet responded or whose response is deemed inadequate.</span></p></td></tr><tr style="height:124pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self-care ADL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2 recommendations as listed, with the following additions for G3:</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer corticosteroids (initial dose of 1 to 2 mg/kg/d prednisone or equivalent) until symptoms improve to G1, and then start taper over 4-6 weeks. Consider IV methylprednisolone, especially if concern for concurrent upper GI inflammation.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Consider early introduction of infliximab or vedolizumab in addition to steroids in patients with high-risk endoscopic features<span class="s9">A </span>on initial endoscopy exam or inadequate response to steroids (persistent symptoms after 3 days).</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider hospitalization for patients with dehydration or electrolyte imbalance.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider repeat colonoscopy in patients who are immunosuppression-refractory.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Should consider permanently discontinuing CTLA-4 agents.</span></p></td></tr><tr style="height:100pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 30pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; urgent intervention indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2-G3 recommendations as listed, with the following additions for G4:</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue treatment.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Should provide inpatient care.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer 1 to 2 mg/kg/d methylprednisolone or equivalent until symptoms improve to G1, and then start taper over 4-6 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider early biologics (infliximab or vedolizumab) if inadequate response to steroids after 3 days.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider lower GI endoscopy if symptoms are refractory despite treatment or there is concern of new infections.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.0. Gastrointestinal Toxicities</p></td></tr><tr style="height:98pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>May consider fecal microbiota transplant,<span class="s9">4,5 </span>JAK inhibitor tofacitinib<span class="s9">6 </span>or IL-12 blocking antibody ustekinumab<span class="s9">7 </span>in patients who are refractory to the previous immunosuppressants.</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients with both irAE-related hepatitis and irAE-related colitis are less common, and management may include permanently discontinuing ICPi and offering other immunosuppressant agents (e.g., prednisone and mycophenolate) that work systemically for both conditions. Infliximab is contraindicated for hepatic irAE.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Currently, enteritis and/or gastritis alone as the cause of gastrointestinal toxicity is uncommon and endoscopy with biopsy is recommended as the evaluation tool. It may be managed similarly to colitis including steroid and/or biologics etc.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.2. Hepatitis</p></td></tr><tr style="height:135pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor patient for abnormal liver blood tests: AST, ALT, and bilirubin prior to each infusion and/or consider weekly if grade 1 LFT elevations. No treatment is recommended for grade 1 LFT abnormality.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Review medications and supplements that may cause hepatotoxicity and rule out abnormal liver enzymes from development or progression of liver metastases.</span></p><p class="s5" style="padding-left: 5pt;text-indent: 18pt;text-align: left;"><span class="s6">  </span><span class="s3">Liver biopsy should be considered if the patient is steroid refractory or if concern for other differential diagnoses that would alter medical management. For grade ≥2:</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6"> </span><span class="s3">Work up for other causes of elevated liver enzymes (e.g. viral hepatitis, alcohol history, iron studies, thromboembolic event, or potential liver metastasis from primary malignancy) by doing blood work and imaging (ultrasound and cross-sectional imaging). If suspicion for primary autoimmune hepatitis is high, can consider ANA/ASMA/ANCA. If patients with elevated ALKP alone, GGT should be tested. For isolated elevation of transaminases, consider checking CK for other etiologies.</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic (AST or ALT &gt;ULN to 3.0× ULN and/or total bilirubin &gt;ULN to</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">1.5× ULN)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi with close monitoring; consider alternate etiologies.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider monitoring labs 1 to 2 times weekly.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Manage with supportive care for symptom control.</span></p></td></tr><tr style="height:137pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Asymptomatic (AST or ALT &gt;3.0 to</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">≤5× ULN and/or total bilirubin &gt;1.5 to ≤3× ULN)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients should be advised to stop unnecessary medications and any known hepatotoxic drugs. Temporarily hold other potentially hepatotoxic oncologic agents.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">For grade 2 hepatic toxicity, may administer steroid (0.5-1mg/kg day prednisone) or equivalent if no improvement is seen after 3-5 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Increase frequency of monitoring to every 3 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If inadequate improvement after 3 days, consider adding mycophenolate mofetil.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May initiate steroid taper when symptoms improve to ≤ G1 and may resume ICPi treatment when steroid ≤</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">10mg/d. Taper over at least 1 month.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider hepatology consult for G2 and above.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May resume if recover to ≤ G1 on prednisone ≤ 10mg/d.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">2.0. Gastrointestinal Toxicities</p></td></tr><tr style="height:161pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">AST or ALT 5-20× ULN and/or total bilirubin 3-10× ULN, OR symptomatic liver dysfunction; fibrosis by biopsy; compensated cirrhosis; reactivation of chronic hepatitis</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2 recommendations as listed, with the following additions for G3:</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider permanently discontinuing ICPi if asymptomatic; permanently discontinue if symptomatic.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Immediately start steroid 1-2 mg/kg methylprednisolone or equivalents.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6"> </span>If steroid refractory, consider liver biopsy to rule out NASH, tumor, cholestatic variants, other drug-related hepatic inflammation, infection, or other autoimmune entity and consider adding azathioprine<span class="s9">B </span>or mycophenolate<span class="s9">C </span>if infectious cause is ruled out.</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Labs daily or every other day; consider inpatient monitoring for patients with AST/ALT &gt; 8 × ULN and/or elevated total bilirubin 3 × &gt; ULN.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If no improvement is achieved with steroid or for patients on ICPi therapy combined with a novel agent, with standard chemotherapy, or with targeted therapy, refer to hepatologist for further pathologic evaluation of hepatitis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Steroid taper can be attempted around 4-6 weeks when ≤ G1, re-escalate if needed, optimal duration unclear.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider transfer to tertiary care facility if necessary.</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-left: 5pt;padding-right: 16pt;text-indent: 0pt;text-align: justify;">G4: <span class="s3">AST or ALT &gt;20× ULN and/or total bilirubin &gt;10× ULN OR decompensated liver function (e.g., ascites,</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">coagulopathy, encephalopathy, coma)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-top: 11pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G3 recommendations as listed, with the following additions for G4:</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer 2 mg/kg/d methylprednisolone equivalents.</span></p></td></tr><tr style="height:25pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional considerations:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Infliximab is contraindicated for immune-related hepatitis.</span></p></td></tr></table><p class="s11" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">A <span class="s12">High-risk endoscopic features include large deep ulceration, multiple ulcers, and extensive colitis beyond left colon.</span>1,2</p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">B <span class="s12">Anecdotal experience suggests azathioprine may be beneficial in steroid-refractory immune-related hepatitis. If using azathioprine, should test for thiopurine methyltransferase (TPMT) deficiency.</span></p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;line-height: 12pt;text-align: left;">C <span class="s12">A case study reports use of mycophenolate mofetil in steroid-refractory immune-related hepatitis with some success.</span>8</p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">3.0. Lung Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">3.1. Pneumonitis</p></td></tr><tr style="height:62pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation</p><p class="s3" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Should include the following: Pulse oximetry, CT chest<span class="s9">39 </span>preferably with contrast if concerned for other etiologies such as pulmonary embolus.</p><p class="s5" style="padding-left: 41pt;padding-right: 21pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">For G2 or higher, may include the following infectious workup: nasal swab, sputum culture, and sensitivity, blood culture and sensitivity, urine culture, and sensitivity.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">COVID-19 evaluation – per institutional guidelines where relevant.</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:87pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: justify;">G1: <span class="s3">Asymptomatic; confined to one lobe of the lung or &lt; 25% of lung parenchyma; clinical or diagnostic observations only</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi or proceed with close monitoring.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor patients weekly with history and physical examination, pulse oximetry; may also offer chest imaging (CXR, CT) if uncertain diagnosis and/or to follow progress.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Repeat chest imaging in 3-4 weeks or sooner if patient becomes symptomatic.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">In patients who have had baseline testing, may offer a repeat spirometry or DLCO in 3-4 weeks.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May resume ICPi with radiographic evidence of improvement or resolution if held. If no improvement, should treat as G2.</span></p></td></tr><tr style="height:88pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 8pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Symptomatic; Involves more than one lobe of the lung or 25-50% of lung parenchyma; medical intervention indicated; limiting instrumental ADL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until clinical improvement to ≤G1.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Prednisone 1-2 mg/kg/d and taper over 4-6 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider bronchoscopy with BAL +/- transbronchial biopsy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider empiric antibiotics if infection remains in the differential diagnosis after workup.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor at least once per week with history and physical examination, pulse oximetry, consider radiological imaging; if no clinical improvement after 48-72 hours of prednisone, treat as grade 3.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s6">  </span><span class="s3">Pulmonary and infectious disease consults if necessary.</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Severe symptoms; Hospitalization required: Involves all lung lobes or &gt; 50% of lung parenchyma; limiting self-care</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">ADL; oxygen indicated.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Empiric antibiotics may be considered.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Methylprednisolone IV 1-2 mg/kg/d.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If no improvement after 48 hours, may add immunosuppressive agent. Options include infliximab or mycophenolate mofetil IV or IVIG or cyclophosphamide. Taper corticosteroids over 4-6 weeks.</span><span class="s9">D</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Pulmonary and infectious disease consults if necessary.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May consider bronchoscopy with BAL ± transbronchial biopsy if patient can tolerate.</span></p></td></tr><tr style="height:39pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-top: 1pt;padding-left: 5pt;padding-right: 42pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening respiratory compromise; urgent intervention indicated (intubation)</span></p></td></tr></table><p class="s11" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;line-height: 117%;text-align: left;">D <span class="s12">Subset of patients may develop chronic pneumonitis and may require longer taper. Chronic pneumonitis is a described phenomenon where the incidence is not known, but &lt; 2%.</span>9</p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.1. Thyroid</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.1.1. Primary Hypothyroidism</p></td></tr><tr style="height:75pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">TSH, with the option of also including FT4, can be checked every 4-6 weeks as part of routine clinical monitoring for asymptomatic patients on ICPi therapy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">TSH and FT4 should be used for case detection in symptomatic patients.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Low TSH with a low FT4 is consistent with central hypothyroidism. Evaluate as per hypophysitis (see 4.3).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Commonly develops after thyrotoxicosis phase of thyroiditis (4.1.2).</span></p></td></tr><tr style="height:23pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:24pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">TSH &gt; 4.5 and &lt; 10</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">mIU/L and asymptomatic</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Should continue ICPi with monitoring of TSH (option for FT4) every 4-6 weeks as part of routine care.</span></p></td></tr><tr style="height:100pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 15pt;text-indent: 0pt;text-align: justify;">G2: <span class="s3">Moderate symptoms, able to perform ADL. TSH persistently &gt; 10 mIU/L</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May continue or hold ICPi until symptoms resolve to baseline.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Consider endocrine consultation for unusual clinical presentations, concern for central hypothyroidism, or difficulty titrating hormone therapy.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Prescribe thyroid hormone supplementation in symptomatic patients with any degree of TSH elevation or in asymptomatic patients with TSH levels that persist over 10 mIU/L (measured 4 weeks apart).</span><span class="s9">10,11</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor TSH every 6-8 weeks while titrating hormone replacement to goal of TSH within the reference range.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">FT4 can be used to help interpret ongoing abnormal TSH levels on therapy, as TSH may take longer to normalize.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Once adequately treated, repeat testing every 6-12 months or as indicated for a change in symptoms.</span></p></td></tr><tr style="height:100pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe symptoms, medically significant or life- threatening consequences, unable to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until symptoms resolve to baseline with appropriate supplementation</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation to assist with rapid hormone replacement.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hospital admission for developing myxedema (bradycardia, hypothermia, altered mental status).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Inpatient endocrinology consultation can assist with IV levothyroxine dosing, steroids, and supportive care.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">If there is uncertainty about whether primary or central hypothyroidism is present, hydrocortisone should be given before thyroid hormone is initiated.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Myxedema coma is a life-threatening emergency requiring admission and a high level of care.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Thyroid supplementation and reassessment as in G2.</span></p></td></tr><tr style="height:123pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">For patients without risk factors (i.e., &lt; 70 years old, not frail, and without cardiac disease or multiple comorbidities), full replacement can be estimated using ideal body weight for a dose of approximately 1.6 mcg/kg/d.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">For those over age 70 and/or frail patients with multiple comorbidities (including cardiac disease), consider titrating up from a lower starting dose of 25- 50 µg.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Elevated TSH can be seen in the recovery phase of thyroiditis. In asymptomatic patients with FT4 that remains in the reference range, it is an option to monitor before treating to determine whether there is recovery to normal within 3-4 weeks. Progression or development of symptoms should be treated as per G2.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Development of a low TSH on therapy suggests over-treatment or recovery of thyroid function and dose should be reduced or discontinued with close follow up.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.1.2. Thyrotoxicosis</p></td></tr><tr style="height:63pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">TSH can be checked every 4-6 weeks as part of routine clinical monitoring for asymptomatic patients on ICPi therapy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">TSH and FT4 should be used for case detection in symptomatic patients. T3 can be helpful in highly symptomatic patients with minimal FT4 elevations.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Low TSH with a low FT4 is consistent with central hypothyroidism. Evaluate as per hypophysitis (see 4.3).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider TSH receptor antibody testing if there are clinical features and suspicion of Graves’ disease (e.g., ophthalmopathy and T3 toxicosis).</span></p></td></tr><tr style="height:23pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:75pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic or mild symptoms</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Can continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Beta-blocker (e.g., atenolol or propranolol) for symptomatic relief.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Close monitoring of thyroid function every 2-3 weeks after diagnosis to catch the transition to hypothyroidism, the most common outcome for transient subacute thyroiditis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Treat transition to elevated TSH and low FT4 as for primary hypothyroidism (see 4.1.1).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">For persistent thyrotoxicosis (&gt; 6 weeks) consider endocrine consultation for additional work up.</span></p></td></tr><tr style="height:75pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate symptoms, able to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi until symptoms return to baseline.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Beta-blocker (e.g., atenolol or propranolol) for symptomatic relief.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hydration and supportive care.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">For persistent thyrotoxicosis (&gt; 6 weeks) refer to endocrinology for additional workup and possible medical thyroid suppression.</span></p></td></tr><tr style="height:87pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe symptoms, medically significant or life- threatening consequences, unable to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until symptoms resolve to baseline with appropriate therapy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation for all patients.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Beta-blocker (e.g., atenolol or propranolol).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hydration and supportive care.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 35pt;text-indent: -18pt;line-height: 12pt;text-align: justify;"><span class="s6">  </span><span class="s3">Consider hospitalizing patients in severe cases as in-patient endocrine consultation can guide the use of additional medical therapies including steroids, potassium iodide (SSKI), or thionamide (methimazole or propylthiouracil) and possible surgery.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2. Adrenal</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.2.1. Primary Adrenal Insufficiency</p></td></tr><tr style="height:88pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluate AM levels of ACTH (if &gt; 2× ULN) and cortisol level (if &lt; 3 µg/dL).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Basic Metabolic Panel (Na, K, CO2, and glucose).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Renin and aldosterone.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider standard dose ACTH stimulation test for indeterminate results (AM cortisol &gt; 3 µg/dL and &lt; 15 µg/dL).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluate for precipitating cause of crisis such as infection.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Adrenal CT for metastasis or hemorrhage (most common causes of primary AI).</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:23pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:26pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to endocrinology.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Education on steroid stress dosing, emergency injections, and a medical alert bracelet/necklace, accessory, or system.</span></p></td></tr><tr style="height:100pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic or mild symptoms</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi until patient is stabilized on replacement hormone.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate replacement therapy with hydrocortisone (15-20 mg in divided doses – see additional considerations).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Titrate hydrocortisone to maximum of 30 mg daily total dose for residual symptoms of AI.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Reduce maintenance dosing for symptoms of iatrogenic Cushing’s syndrome (e.g., bruising, thin skin, edema, weight gain, hypertension, and hyperglycemia).</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Most primary AI will also require fludrocortisone (starting dose 0.5-0.1 mg/d). Adjust based on volume status, sodium level, and renin response (target upper half of the reference range).</span></p></td></tr><tr style="height:100pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate symptoms, able to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi until patient is stabilized on replacement hormone.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">See in clinic to assess need for hydration, supportive care, and hospitalization.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Initiate outpatient corticosteroid treatment at 2-3 times maintenance (e.g. hydrocortisone 30-50 mg total dose or prednisone 20 mg daily) to manage acute symptoms.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate fludrocortisone (0.5-0.1 mg/d).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Decrease stress dose corticosteroids down to maintenance doses after 2 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Maintenance therapy as in G1.</span></p></td></tr><tr style="height:87pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe symptoms, medically significant or life- threatening consequences, unable to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until patient is stabilized on replacement hormone.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Inpatient management may be needed to provide:</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Normal saline (at least 2L).</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">IV Stress dose steroids: Hydrocortisone 50-100 mg Q 6-8 hours initial dosing.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Taper stress dose corticosteroids down to oral maintenance doses over 5-7 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Maintenance therapy as in G1.</span></p></td></tr><tr style="height:159pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Primary and secondary adrenal insufficiency can be distinguished by the relationship between ACTH and cortisol. If the ACTH is low with low cortisol, then management is as per hypophysitis in section 4.3 for secondary (central) adrenal insufficiency.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Using hydrocortisone allows for re-creation of the diurnal rhythm of cortisol. Typically, 2/3 of the dose is given in the morning and 1/3 in the early afternoon. Long-acting steroids such as prednisone, rather than short-acting hydrocortisone, carry risk of over replacement but can be used in special circumstances, for example, if a patient is not able to adhere to a short-acting steroid regimen. Hydrocortisone 20 mg is equivalent to prednisone 5 mg.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">DHEA replacement is controversial but deficiency can be tested and replacement considered in women with low libido and/or energy who are judged to be otherwise well replaced.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">All patients need education on stress dosing for sick days, use of emergency injectables, when to seek medical attention for impending adrenal crisis, and a medical alert bracelet/necklace for adrenal insufficiency to trigger stress dose corticosteroids by emergency medical personnel. Therefore, early endocrinology consultation is appropriate.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation should be part of planning prior to surgery or high-stress treatments such as cytotoxic chemotherapy at any time during a</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">patient’s care.</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.3. Pituitary</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.3.1. Hypophysitis</p></td></tr><tr style="height:111pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluate ACTH (AM), cortisol (AM), TSH, free T4, and electrolytes.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider standard dose ACTH stimulation testing for indeterminate results (AM cortisol &gt; 3 µg/dL and &lt; 15 µg/dL).</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider evaluating LH and testosterone in males, FSH, and estrogen in premenopausal females with fatigue, loss of libido and mood changes, or oligomenorrhea.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Consider MRI brain w/wo contrast with pituitary/sellar cuts in all patients with new hormonal deficiencies and particularly those with multiple endocrine abnormalities ± new severe headaches or complaints of vision changes.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Perform MRI brain w/wo contrast with pituitary/sellar cuts for all patients presenting with diabetes insipidus (DI is most commonly from metastatic disease).</span></p></td></tr><tr style="height:23pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:26pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to endocrinology</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Education on steroid stress dosing, emergency injections, and a medical alert bracelet/necklace, accessory, or system.</span></p></td></tr><tr style="height:123pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 12pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic or mild symptoms</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi until patient is stabilized on replacement hormones.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Corticosteroid replacement for adrenal insufficiency with preference for hydrocortisone (15-20 mg in divided doses – see additional considerations section 4.2).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate other hormone replacement only after any needed adrenal replacement to avoid precipitating adrenal crisis.</span></p><p class="s7" style="padding-left: 77pt;text-indent: -18pt;text-align: left;">o <span class="s3">Thyroid hormone replacement if needed using dosing as above for primary hypothyroidism, with a goal FT4 in the upper half of the reference range (TSH is not accurate in central hypothyroidism).</span></p><p class="s7" style="padding-left: 77pt;padding-right: 8pt;text-indent: -18pt;text-align: left;">o <span class="s3">Testosterone or estrogen therapy if needed in those without contraindications (e.g. prostate cancer, breast cancer, or history of DVT).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Recommend education on stress dosing, emergency injectable, and a medical alert or necklace accessory or system.</span></p></td></tr><tr style="height:87pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate symptoms, able to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi until patient is stabilized on replacement hormones.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Clinic evaluation to assess need for steroids and volume repletion.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider oral pulse dose therapy in patients with MRI findings of swelling or threatened optic chiasm compression (prednisone 1 mg/kg/d (or equivalent)). Taper over 1-2 weeks and transition to physiologic maintenance therapy once down to 5 mg prednisone equivalent.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hormonal supplementation as in G1.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:123pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe symptoms, medically significant or life- threatening consequences, unable to perform ADL</span></p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until patient is stabilized on replacement hormones.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hospitalize or make an ED referral for:</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Normal saline (at least 2L) or monitored free water replacement if DI.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">IV Stress dose steroids: Hydrocortisone 50-100 mg Q6-8 hours initial dosing.</span></p><p class="s7" style="padding-left: 77pt;padding-right: 8pt;text-indent: -18pt;text-align: left;">o <span class="s3">Oral pulse dose therapy with Prednisone 1-2mg/kg daily (or equivalent) tapered over at least 1-2 weeks to physiologic maintenance in patients with significant swelling on MRI, optic chiasm compression, severe headache or visual changes.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Taper stress dose corticosteroids down to oral maintenance doses over 5-7 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Maintenance therapy as in G1.</span></p></td></tr><tr style="height:208pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Please be aware of the need to <b>start corticosteroids first </b>when planning hormone replacement therapy for multiple deficiencies as other hormones accelerate the clearance of cortisol and can precipitate adrenal crisis.</p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">ACTH stimulation can give a false negative result early in hypophysitis as adrenal reserve declines slowly after pituitary stimulation is lost. In the presence of clinical uncertainty, opt for replacement and test for ongoing need at 3 months.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If prednisone or equivalent is started for mild or moderate symptoms, consider lower doses (average daily dose over two months of less than 7.5 mg) due to report of reduced survival on higher doses</span><span class="s9">12</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">All patients need education on stress dosing for sick days, use of emergency steroid injectables, when to seek medical attention for impending adrenal crisis, and a medical alert bracelet for adrenal insufficiency to trigger stress dose corticosteroids by EMS.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;text-align: justify;"><span class="s6">  </span><span class="s3">Steroid use for other irAEs can cause isolated central adrenal insufficiency with a low ACTH. In a patient with adrenal insufficiency, a recent history of treatment with corticosteroids, and no other central hormone deficiencies, the HPA axis should be tested for recovery after 3 months of maintenance therapy with hydrocortisone.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Laboratory confirmation of AI should not be attempted in patients given high dose corticosteroids for other irAEs until treatment is ready to be discontinued.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">AM cortisol in a patient on corticosteroids is not diagnostic as the measurement of therapeutic steroids in the assay for cortisol varies. Hydrocortisone needs to be held for 24 hours and other steroids for longer before endogenous function is assessed. Consider consulting endocrinology for recovery and weaning protocols using hydrocortisone in patients with symptoms of AI after weaning off corticosteroids.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.4. Diabetes</p></td></tr><tr style="height:98pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor patients for symptoms of new or worsening DM (polyuria, polydipsia, fatigue).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor glucose at baseline and with each treatment cycle while on therapy and at follow-up visits for at least 6 months.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Laboratory evaluation in suspected CIADM should include:</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Urine and/or serum ketones.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Anion gap on a metabolic panel.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Anti-GAD or anti-islet cell antibodies.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 11pt;text-align: left;">o <span class="s3">C-peptide levels.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:22pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:109pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic or mild symptoms; T2DM with fasting glucose value &gt; ULN to 160 mg/dL (&gt; ULN to 8.9 mmol/L;). No evidence of CIADM such as ketoacidosis or laboratory</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">evidence of pancreatic autoimmunity.</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Can continue ICPi with close clinical follow-up and laboratory evaluation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Refer to PCP for additional management or:</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">May initiate oral therapy for those with new onset T2DM.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Intensify medical therapy for those with worsening T2DM.</span></p></td></tr><tr style="height:108pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate symptoms, able to perform ADL; T2DM with fasting glucose value &gt; 160 to 250 mg/dL (&gt; 8.9 to</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">13.9 mmol/L). No ketoacidosis or metabolic derangements but</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">other evidence of CIADM at</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">any glucose level.</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 11pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May hold ICPi until glucose control is obtained.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent endocrine consultation for any patient with new-onset CIADM.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate insulin for CIADM (or as default therapy if there is any question about the diagnosis).</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Referral to ED or hospital admission if unable to initiate therapy, urgent outpatient specialist evaluation is not available, developing ketoacidosis or other concern for CIADM.</span></p></td></tr><tr style="height:121pt"><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe symptoms, medically significant or life- threatening consequences, unable to perform ADL; G3:</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt; 250 - 500 mg/dL (&gt; 13.9 -</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">27.8 mmol/L); G4: &gt; 500</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">mg/dL (&gt; 27.8 mmol/L).</p><p class="s3" style="padding-left: 5pt;padding-right: 58pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Ketoacidosis or other metabolic abnormality.</p></td><td style="width:585pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi until glucose control is obtained with reduction of toxicity to ≤ G1.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit for inpatient management of DKA, volume and electrolyte resuscitation and insulin initiation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Endocrine consultation for all patients.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Insulin therapy appropriate for all patients.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">4.0. Endocrine Toxicities</p></td></tr><tr style="height:171pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Insulin therapy should be used in any case with significant hyperglycemia pending additional diagnostic workup if mechanism of DM is not known.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Long-acting insulin therapy alone is not sufficient for CIADM because of the absence of pancreatic function after beta-cell destruction.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Starting total daily requirement can be estimated at 0.3-0.4 units/kg/d.</span></p><p class="s7" style="padding-left: 77pt;padding-right: 10pt;text-indent: -18pt;text-align: left;">o <span class="s3">Half of daily requirements are typically given in divided doses as prandial coverage while half should be administered as a once daily long- acting homolog. This requires self-monitoring 4 or more times daily or the use of a continuous glucose monitor.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Sliding scale insulin can be used in conjunction with multiple daily injection regimens to accommodate the variability in glucose levels.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Decreased requirements after the initial acute admission for DKA are commonly seen in the so-called honeymoon period.</span></p><p class="s7" style="padding-left: 77pt;text-indent: -18pt;text-align: left;">o <span class="s3">Education is critical to learn skills like responding to hypoglycemia, anticipating exercise, monitoring for DKA, or carbohydrate counting and to transition to technologies such as insulin pumps. Early endocrinology consultation is a high priority for all patients.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">T2DM patients will need to increase the frequency of self-monitoring as therapy intensifies and agents that can cause hypoglycemia are added to their regimen.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Steroids can exacerbate post-prandial hyperglycemia and endocrinology consult should be considered for initiating or managing insulin in patients with T2DM being started on high dose steroids. If insulin is used, the doses generally need to be adjusted again as steroids are tapered down.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.0. Musculoskeletal Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.1. Inflammatory Arthritis</p></td></tr><tr style="height:234pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Complete rheumatologic history and examination of all peripheral joints for tenderness, swelling, and range of motion. Examination of the spine.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider plain X-ray/imaging to exclude metastases and evaluate joint damage (erosions) if appropriate.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider autoimmune blood panel including ANA, RF, anti-CCP, and inflammatory markers (ESR and CRP) if symptoms persist. If symptoms are suggestive of reactive arthritis or affect the spine, consider HLA B27 testing.</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G2:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Complete history and examination as above; laboratory tests as above.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Consider US ± MRI imaging of affected joints if clinically indicated (e.g., persistent arthritis unresponsive to treatment, suspicion for differential diagnoses such as metastatic lesions or septic arthritis). Consider arthrocentesis if septic arthritis or crystal-induced arthritis are suspected.</span></p><p class="s5" style="padding-left: 5pt;padding-right: 183pt;text-indent: 18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider early referral to a rheumatologist, if there is joint swelling (synovitis) or if symptoms persist &gt; 4 weeks. G3-4:</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">As for grade 2.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Seek rheumatologist advice and review.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Test for viral hepatitis B, C, and latent/active TB test prior to DMARD treatment. Repeated screening labs annually in patients who require biologic treatment for &gt; 1 year until treatment is completed.</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Monitoring:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6"> </span><span class="s3">Patients with IA should be monitored with serial rheumatologic examinations, including inflammatory markers, every 4-6 weeks after treatment is instituted.</span></p></td></tr><tr style="height:23pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:25pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Clinicians should follow reports of new joint pain to determine if IA is present. Question whether symptoms new since receiving ICPi.</span></p></td></tr><tr style="height:36pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild pain with inflammation, erythema,</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">or joint swelling</p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate analgesia with acetaminophen and/or NSAIDs.</span></p></td></tr><tr style="height:100pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 8pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Escalate analgesia and consider higher doses of NSAIDs as needed.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If inadequately controlled, initiate prednisone 10-20 mg/d or equivalent.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">If improvement, slow taper according to response during the next 4-6 weeks. If no improvement after initial 4 weeks, treat as G3.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If unable to lower corticosteroid dose to below 10mg/d after 6-8 weeks, consider DMARD.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider intra-articular steroid injections for large joints.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to rheumatology.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.0. Musculoskeletal Toxicities</p></td></tr><tr style="height:99pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-top: 7pt;padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; disabling; limiting self- care ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily and may resume in consultation with rheumatology, if recover to ≤ G1.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate oral prednisone 0.5-1 mg/kg.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If failure of improvement after 2 weeks or worsening in meantime, consider synthetic or biologic DMARD.</span></p><p class="s7" style="padding-left: 59pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Synthetic: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine alone or in combination.</span></p><p class="s3" style="padding-left: 77pt;padding-right: 25pt;text-indent: -18pt;text-align: left;"><span class="s7">o </span>Biologic: Consider anti-cytokine therapy such as TNFα or IL-6 antagonists. Note: As a caution, IL6 inhibition can cause intestinal perforation.<span class="s9">13 </span>While this is extremely rare, it should not be used in patients with concomitant immune-related colitis.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to rheumatology.</span></p></td></tr><tr style="height:62pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Early recognition is critical to avoid erosive joint damage.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 33pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Corticosteroids can be used as part of initial therapy in IA, but due to likely prolonged treatment requirements, physicians should consider starting steroid-sparing agents earlier than one would with other irAEs.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s6">  </span><span class="s3">Oligoarthritis can be treated early on with intra-articular steroids, consider early referral.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.2. Myositis</p></td></tr><tr style="height:246pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Complete rheumatologic and neurologic history regarding differential diagnosis and rheumatologic and neurologic examination including muscle strength, and examination of the skin for findings suggestive of dermatomyositis. Muscle weakness is more typical of myositis than pain. Consider pre- existing conditions that can cause similar symptoms.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Blood testing to evaluate muscle inflammation; CK and aldolase. Transaminases (AST, ALT) and LDH can also be elevated.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Troponin to evaluate myocardial involvement. Other cardiac testing such as ECG and echocardiogram or cardiac MRI (see CV section for further details).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Autoantibody testing to evaluate possible concomitant myasthenia gravis (anti-AChR and anti-striational antibodies)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Inflammatory markers (ESR and CRP).</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider electromyography (EMG), imaging (MRI) and/or biopsy on an individual basis when diagnosis is uncertain and overlap with neurologic syndromes such as myasthenia gravis is suspected.</span></p><p class="s3" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Consider paraneoplastic autoantibody testing for myositis (e.g. anti-TIF1<span class="s13"></span>, anti-NXP2, and other myositis autoantibodies as indicated), especially if patient had muscle-related manifestations before receiving ICPi</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urinalysis for rhabdomyolysis.</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Monitoring:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CK, ESR, CRP, aldolase if CK has not been elevated.</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1<span class="s3">: Complete examination and laboratory work-up as above.</span></p><p class="s2" style="padding-left: 5pt;padding-right: 163pt;text-indent: 0pt;text-align: left;">G2<span class="s3">: Complete history and examination as above; autoimmune myositis blood panel; EMG, MRI imaging of affected joints Early referral to a rheumatologist or neurologist.</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">G3-4<span class="s3">: As for grade 2. Urgent referral to a rheumatologist or neurologist.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.0. Musculoskeletal Toxicities</p></td></tr><tr style="height:22pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management of Myositis Alone<span class="s14">E</span></p></td></tr><tr style="height:50pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild weakness with or without pain</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If CK and/or aldolase are elevated and patient has muscle weakness may offer oral corticosteroids, starting prednisone at 0.5mg/kg/d. Offer analgesia with acetaminophen or NSAIDs for myalgia if there are no contraindications.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding statins.</span></p></td></tr><tr style="height:99pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate weakness with or without pain limiting age-appropriate instrumental ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily and may resume upon symptom control, if CK is normal and prednisone dose &lt; 10mg; if worsens, treat as per G3.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">NSAIDs as needed.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to rheumatologist or neurologist.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If CK is elevated (×3 ULN or more), initiate prednisone or equivalent at 0.5-1 mg/kg/d.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May require permanent discontinuation of ICPi in cases with G2 symptoms if patient had other objective findings of severe</span></p><p class="s3" style="padding-left: 41pt;padding-right: 13pt;text-indent: 0pt;line-height: 12pt;text-align: left;">muscle involvement such as very elevated enzymes, or extensive involvement as determined by EMG, MRI or histology). ICPi should not be restarted until CK is normal and clinical manifestations of myositis are resolved.</p></td></tr><tr style="height:173pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe weakness with or without pain; limiting self-care ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Consider hospitalization for patients with severe weakness severely limiting mobility, respiratory, dysphagia, or rhabdomyolysis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent referral to rheumatologist and/or neurologist.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate prednisone 1 mg/kg/d or equivalent.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">For patients with severe compromise, start 1-2mg/kg of methylprednisolone IV or higher dose bolus.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider plasmapheresis in patients with acute/severe disease as guided by rheumatology/neurology.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider IVIG therapy, noting onset of action is slower. Note: Plasmapheresis immediately after IVIG will remove immunoglobulin.</span></p><p class="s3" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6"> </span>Consider other immunosuppressant therapy including biologics (e.g. rituximab), TNFα or IL-6 antagonists if symptoms worsen or if no improvement after 2 weeks. Other synthetic immunosuppressants such as methotrexate, azathioprine, or mycophenolate mofetil could be considered for maintenance<span class="s9">F</span>, or if symptoms and CK levels do not resolve entirely after 4 weeks. Rituximab is used in primary myositis.<span class="s9">14</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider permanent discontinuation of ICPi.</span></p></td></tr><tr style="height:38pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Caution is advised with rechallenging.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">With elevated transaminases, consider differential with immune-mediated hepatitis.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.0. Musculoskeletal Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5.3 Polymyalgia-like Syndrome</p></td></tr><tr style="height:121pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1<span class="s3">: Complete rheumatologic history regarding differential diagnosis and examination of all joints and skin. Rarely patients may also develop concomitant GCA. Check for symptoms of temporal arteritis, such as headache, visual disturbances, or jaw claudication. Urgent referral to ophthalmologist if present and consider temporal artery biopsy as permanent visual loss can occur within days of symptom onset.</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">ANA, RF, anti-CCP.</p><p class="s3" style="padding-left: 5pt;padding-right: 499pt;text-indent: 0pt;text-align: left;">CK to evaluate differential diagnosis of myositis. Inflammatory markers (ESR, CRP).</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Monitoring: <span class="s3">ESR, CRP</span></p><p class="s2" style="padding-left: 5pt;padding-right: 224pt;text-indent: 0pt;line-height: 12pt;text-align: left;">≥ G2<span class="s3">: Complete history and examination as above; autoimmune tests as required for differential diagnosis. Early referral to a rheumatologist.</span></p></td></tr><tr style="height:23pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:26pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G1: <span class="s3">Mild stiffness and pain</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate analgesia with acetaminophen and/or NSAIDs if there are no contraindications.</span></p></td></tr><tr style="height:51pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-top: 1pt;padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate stiffness and pain; limiting age- appropriate instrumental ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi and resuming upon symptom control, prednisone &lt; 10mg; if worsens, treat as per G3.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate prednisone 20 mg/d or equivalent. If symptoms improve, start to taper dose after 3-4 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If no improvement or need for higher dosages after 4 weeks, escalate to G3</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider referral to rheumatology.</span></p></td></tr><tr style="height:99pt"><td style="width:126pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 20pt;text-indent: 0pt;text-align: justify;">G3-4: <span class="s3">Severe stiffness and pain; limiting self- care ADL</span></p></td><td style="width:594pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and may resume, in consultation with rheumatology, if recover to ≤ G2. However, note that cases of toxicity returning upon rechallenge have been reported.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Referral to rheumatology.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Should initiate prednisone 40 mg/d or equivalent. If no improvement or need for higher dosages for prolonged time, may offer a steroid sparing agent such as synthetic drugs (e.g. methotrexate) or biologic agents (e.g. IL-6 antagonists). Note: As caution, IL-6 inhibition can cause intestinal perforation. While this is extremely rare, it should not be used in patients with immune-related colitis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider admission of patients with severe symptoms.</span></p></td></tr><tr style="height:37pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">IL-6 antagonists may be the preferred steroid-sparing agents for management of polymyalgia-like syndrome as they are already approved for use in patients with GCA.</span></p></td></tr></table><p class="s11" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">E <span class="s12">Patients with myasthenia gravis-like syndrome or myocarditis and concomitant myositis should be hospitalized, please see neurologic or cardiovascular sections, respectively, for further information.</span></p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;line-height: 12pt;text-align: left;">F <span class="s12">Strongly urge maintenance with synthetic immunosuppressants be undertaken in collaboration with rheumatology or neurology.</span></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.0. Renal Toxicities</p></td></tr><tr style="height:349pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;padding-right: 410pt;text-indent: 0pt;text-align: left;">Nephritis and Renal Dysfunction – Diagnosis and Monitoring Clinical Presentation<span class="s14">G,15 </span>and Diagnosis:</p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Definite ICPi-related nephritis or AKI:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Kidney biopsy-confirmed diagnosis compatible with ICPi nephritis or AKI, and after clinical review of risk factors.<span class="s9">H</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Probable ICPi-related nephritis or acute renal failure:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">BOTH of the following:</p><p class="s3" style="padding-left: 5pt;padding-right: 96pt;text-indent: 0pt;text-align: left;">Sustained increase in serum creatinine ≥50% on at least two consecutive values or need for RRT, after clinical review of risk factors<span class="s9">H </span>Absence of an alternative plausible etiology</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">AND at least one of the following:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Sterile pyuria (≥5 WBCs/hpf)</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Concomitant or recent extrarenal irAE-eosinophilia (≥ 500 cells per µL)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Possible ICPi-related nephritis or acute renal failure:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">BOTH of the following:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Increase in serum creatinine ≥ 50%</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Need for RRT nephritis or AKI is not readily attributable to alternative causes</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Monitoring:</p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">Monitor patients for elevated serum creatinine prior to every dose.</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">Routine urinalysis is not necessary, other than to rule out UTIs etc.</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">For any suspected immune-mediated adverse reactions, exclude other causes (see below).</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">For suspected renal irAE obtain urinalysis, consider referral to nephrology</span></p><p class="s16" style="padding-left: 23pt;padding-right: 6pt;text-indent: -18pt;text-align: left;">•  <span class="s3">For patients receiving combination therapy with immune checkpoint inhibitors and other agents, assess the potential contribution of the non-iCPI treatment to the renal failure</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">Assess for concomitant medications, prescribed and OTC, herbals, vitamins, nephrotoxic agents, or contrast media</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">•  <span class="s3">If no potential alternative cause of AKI is identified, then one can assume it is ICPi related and should forego biopsy</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">•  <span class="s3">Swift treatment of autoimmune component is important.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.1. Nephritis or Acute Kidney Injury</p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:37pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 25pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G1: <span class="s3">Creatinine level increase of &gt; 0.3 mg/dL; creatinine 1.5 - 2.0× above baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Consider temporarily holding ICPi and/or other potential contributing agents in combination regimens, pending consideration of potential alternative etiologies (recent IV contrast, medications, fluid status, UTI) and baseline renal function. A change that is still &lt;1.5 ULN <i>could </i>be meaningful.</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.0. Renal Toxicities</p></td></tr><tr style="height:124pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Creatinine 2 - 3× above baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consult nephrology.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Evaluate for other causes (recent IV contrast, medications, fluid status, etc.) If other etiologies are ruled out, administer 0.5 to 1 mg/kg/d prednisone equivalents.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If worsening or no improvement after 1 week increase to 1 to 2 mg/kg/d prednisone equivalents and permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If improved to ≤G1, taper steroids over at least 4weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If no recurrence of CRI discuss resumption of ICPi with patient after taking into account the risks and benefits. Resumption of ICPi can be considered once steroids have been successfully tapered to ≤ 10 mg/d or discontinued.</span></p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Creatinine &gt;3× baseline or &gt;4.0</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">mg/dL; hospitalization indicated</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#BEBEBE"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi if ICPi is directly implicated in renal toxicity.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consult nephrology.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluate for other causes (recent IV contrast, medications, fluid status, UTI, etc.).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer corticosteroids (initial dose of 1 to 2 mg/kg/d prednisone or equivalent).</span></p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; dialysis indicated; creatinine 6× above</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">baseline</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2. Nephritis or Acute Kidney Injury – Follow Up</p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:37pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Creatinine level increase of &gt;0.3</span></p><p class="s3" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;line-height: 12pt;text-align: left;">mg/dL; creatinine 1.5 - 2.0× above baseline</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">If improved to baseline</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Resume routine creatinine monitoring</span></p></td></tr><tr style="height:37pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Creatinine 2 - 3× above baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">If improved to Grade 1:</p><p class="s5" style="padding-left: 5pt;padding-right: 14pt;text-indent: 18pt;line-height: 12pt;text-align: left;"><span class="s6"> </span><span class="s3">Taper corticosteroids over at least 4 weeks before resuming treatment with routine creatinine monitoring. If elevations persist &gt; 7 days or worsen and no other cause found, treat as grade 3.</span></p></td></tr><tr style="height:49pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Creatinine &gt;3× baseline or &gt;4.0 mg/dL; hospitalization indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">If improved to Grade 1:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Taper corticosteroids over at least 4 weeks.</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">If elevations persist &gt; 3-5 days or worsen, consider additional immunosuppression (e.g. infliximab, azathioprine, cyclophosphamide (monthly), cyclosporine, mycophenolate).</p></td></tr><tr style="height:49pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; dialysis indicated; creatinine 6× above baseline</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">If improved to Grade 1:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Taper corticosteroids over at least 4 weeks.</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">If elevations persist &gt; 2-3 days or worsen, consider additional immunosuppression (e.g. infliximab, azathioprine, cyclophosphamide (monthly), cyclosporine, mycophenolate).</p></td></tr></table><p class="s11" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">G <span class="s12">Adapted from Gupta 2020.</span>15</p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">H <span class="s12">Risk factors include prior or concomitant nephrotoxic agent(s) use, prior or concomitant extrarenal irAEs.</span></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.1. Myasthenia Gravis</p></td></tr><tr style="height:161pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">AChR and anti-striated muscle antibodies in blood. If AChR antibodies are negative, consider MuSK and LPR4 antibodies in blood—while presence of antibodies is confirmatory, the absence of antibodies does not rule out the syndrome.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Pulmonary function assessment with NIF and VC.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CPK, aldolase, ESR, CRP for possible concurrent myositis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider MRI brain and/or spine depending on symptoms to rule out CNS involvement by disease or alternate diagnosis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Troponin, EKG, and consider TTE and/or cardiac MRI to evaluate concomitant myocarditis (see CV section for further details)</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Electrodiagnostic studies, under neurologic consultation, including neuromuscular junction testing with repetitive stimulation and/or jitter studies, NCS to exclude neuropathy, and needle EMG to evaluate for concomitant myositis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Inflammatory markers (ESR and CRP).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider paraneoplastic workup</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Review and stop medications with known risk of worsening myasthenia: beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics.</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">All grades warrant workup and intervention given potential for progressive MG to lead to respiratory compromise.</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Inpatient admission may be appropriate at all grades.</p></td></tr><tr style="height:12pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">No G1</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">NA</p></td></tr><tr style="height:99pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Some symptoms interfering with ADLs. MGFA severity class I (ocular symptoms and findings only) and MGFA severity class II (mild generalized weakness).</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and may resume in G2 patients (MGFA 1 and 2) only if symptoms resolve and steroid taper completed.</span><span class="s9">16</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Strongly consider in-patient care as patients can deteriorate quickly.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Pyridostigmine starting at 30 mg PO three times a day and gradually increase to maximum of 120mg PO four times a day as tolerated and based on symptoms and wean based on improvement. These procedures should be done in close collaboration with the neurologist.</span></p><p class="s3" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Administer corticosteroids (prednisone 0.5 mg/kg<span class="s9">I </span>orally daily). Wean based on symptom improvement.</p></td></tr><tr style="height:101pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Limiting self-care and aids warranted, weakness limiting walking, ANY dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms or</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">MGFA severity class III-V (moderate to severe generalized weakness to myasthenic crisis)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2 recommendations as listed, with the following additions for G3-4:</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient, may need ICU-level monitoring.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue steroids, taper should begin 3-4 weeks after initiation then wean based on symptom improvement.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate IVIG 2G/kg IV over 5 days (0.4G/kg/d) or plasmapheresis × 5 days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider adding rituximab if refractory to IVIG or plasmapheresis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Frequent pulmonary function assessment.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Daily neurologic review.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.2. Guillain-Barre Syndrome</p></td></tr><tr style="height:137pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurologic consultation</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI spine w/wo contrast (rule out compressive lesion and evaluate for nerve root enhancement/thickening)</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Lumbar puncture: CSF analysis for cell count and differential, cytology for malignant cells, protein, glucose, and viral/bacterial cultures. Note that CSF typically has elevated protein and often elevated WBC as well even though this is not typically seen in classical Guillain-Barre.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider paraneoplastic workup eg ANNA-1 antibody testing</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum antiganglioside antibody tests for GBS and its subtypes (eg, anti-GQ1b for Miller Fisher variant associated with ataxia and ophthalmoplegia).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Flow cytometry in patients with hematological malignancies</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Electrodiagnostic studies (NCS and EMG) to evaluate polyneuropathy</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Pulmonary function testing (NIF or VC)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Frequent neuro checks</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:12pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">All grades warrant workup and intervention given potential for progressive GBS to lead to respiratory compromise. Note, there is no G1 toxicity.</p></td></tr><tr style="height:12pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">No G1</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">NA</p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: </span>s<span class="s3">ome interference with</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">ADLs, symptoms concerning to patient.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admission to inpatient unit with capability of rapid transfer to ICU-level monitoring.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Start IVIG (0.4G/kg/d for 5 days for a total dose of 2G/kg) or plasmapheresis. Note: plasmapheresis immediately after IVIG will remove immunoglobulin.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Corticosteroids are usually not recommended for idiopathic GBS, however in ICPi-related forms, a trial is reasonable (methylprednisolone 2-4 mg/kg/d), followed by slow steroid taper. Pulse steroid dosing (methylprednisolone 1 gram daily for 5 days) may also be considered for G3-4 along with IVIG or plasmapheresis. After pulse steroids, taper steroids over 4-6 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Frequent neuro checks and pulmonary function monitoring.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Monitor for concurrent autonomic dysfunction.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Non-opioid management of neuropathic pain, for example, pregabalin, gabapentin, or duloxetine.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Treatment of constipation/ileus.</span></p></td></tr><tr style="height:137pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: limiting self-care and aids warranted, weakness limiting walking, ANY dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms.</span></p></td></tr><tr style="height:25pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Extreme caution with rechallenging for severe cases after complete resolution of symptoms and tapered off immunosuppression</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.3. Peripheral Neuropathy</p></td></tr><tr style="height:148pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider neurology consultation to guide neuropathy phenotype determination and workup</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum testing for reversible neuropathy causes: HbA1c, vitamin B12, TSH, vitamin B6, folate, serum protein electrophoresis, and immunofixation, CPK</span></p><p class="s5" style="padding-left: 41pt;padding-right: 23pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider additional testing guided by neuropathy phenotype: ANA, ESR, CRP, ANCA, anti-Smooth muscle, SSa/SSb, RNP, anti-dsDNA, ganglioside ab, anti-MAG, anti-Hu (ANNA-1 ab), thiamine, Lyme, hepatitis B or C, HIV</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider MRI spine w/wo contrast</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2<span class="s3">: In addition to the above:</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI spine advised, MRI brain if cranial nerve involvement, MRI plexus if concern for plexus involvement</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider lumbar puncture: CSF analysis for cell count and differential, cytology for malignant cells, protein, glucose, and viral or bacterial cultures.</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider EMG/NCS</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">G3-4<span class="s3">: go to GBS algorithm</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild: no interference with function and symptoms not concerning to patient. Note: any cranial nerve problem</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">should be managed as moderate</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Low threshold to hold ICPi and monitor symptoms for a week. If to continue, monitor very closely for any symptom progression.</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: some interference with ADLs, symptoms concerning to patient (i.e. pain but no weakness or gait</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">limitation).</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and resume once return to ≤ G1.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initial observation OR initiate prednisone 0.5-1mg/kg/d (if progressing from mild).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Gabapentin, pregabalin, or duloxetine for pain.</span></p></td></tr><tr style="height:72pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: limiting self-care and aids warranted, weakness limiting walking or respiratory problems (i.e. leg weakness, foot drop, rapidly ascending sensory changes). Severe may be GBS and</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">should be managed as such.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-top: 10pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate IV methylprednisolone 2-4 mg/kg/d and proceed as per GBS management</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.4. Autonomic Neuropathy</p></td></tr><tr style="height:99pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">An evaluation by neurologist or relevant specialist depending on organ system, with testing which may include:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Screen for other causes of autonomic dysfunction: diabetic screen, adrenal insufficiency, HIV, paraproteinemia, amyloidosis, botulism, consider chronic</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">diseases such as Parkinson’s and other autoimmune screen.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Orthostatic vital signs.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider electrodiagnostic studies (NCS and EMG) to evaluate for concurrent polyneuropathy.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider paraneoplastic autoimmune dysautonomia antibody testing (eg, anti-ganglionic AChR, ANNA-1, and N-type voltage-gated calcium channel antibodies).</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:37pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild: no interference with function and symptoms not concerning to</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">patient.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-top: 5pt;padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Low threshold to hold ICPi and monitor symptoms for a week. If to continue, monitor very closely for any symptom progression.</span></p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: some interference with ADLs, symptoms concerning to patient.</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and resume once return to ≤ G1 and off prednisone if used.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initial observation OR initiate prednisone 0.5-1mg/kg/d (if progressing from mild).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p></td></tr><tr style="height:51pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: limiting self-care and aids warranted.</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Initiate methylprednisolone 1 g daily × 3 days followed by oral steroid taper.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.5. Aseptic Meningitis</p></td></tr><tr style="height:87pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI brain w/wo contrast with pituitary or sellar cuts protocol.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">AM cortisol, ACTH to rule out adrenal insufficiency.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Strongly consider lumbar puncture with CSF analysis for opening pressure, cell count and differential, cytology for malignant cells that could indicate leptomeningeal metastases, protein, glucose, gram stain, viral/bacterial cultures, PCR for HSV, and other viral PCRs depending on suspicion.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May see elevated WBC in CSF with normal glucose, normal culture, and gram stain. May see reactive lymphocytes, neutrophils, or histiocytes on cytology.</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild: no interference with function and symptoms not concerning to patient. Note: any cranial nerve problem</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">should be managed as moderate.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="3" bgcolor="#F1F1F1"><p style="padding-top: 5pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits.</span><span class="s9">17</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider neurology consult</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider empiric antiviral (IV acyclovir) and antibacterial therapy until CSF results.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Once bacterial and viral infection negative, may closely monitor off corticosteroids or consider oral prednisone 0.5-1 mg/kg/d or IV methylprednisolone 1 mg/kg/d if moderate or severe symptoms.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Steroids can be tapered after 2-4 weeks, monitoring for symptom recurrence.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider hospitalization for G3-4.</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: some interference with ADLs, symptoms concerning to patient (i.e. pain but no weakness or gait</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">limitation).</p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: limiting self-care and aids</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">warranted</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.6. Encephalitis</p></td></tr><tr style="height:148pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurologic consultation.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI brain w/wo contrast may reveal T2/FLAIR changes typical of what is seen in autoimmune encephalopathies or limbic encephalitis or may be normal.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Lumbar puncture with CSF analysis for opening pressure, cell count and differential, cytology for malignant cells that could indicate leptomeningeal metastases, protein, glucose, gram stain, viral/bacterial cultures, PCR for HSV and other viral PCRs depending on suspicion, oligoclonal bands, autoimmune encephalopathy, and paraneoplastic panels.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May see elevated WBC with lymphocytic predominance and/or elevated protein.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">EEG to evaluate for subclinical seizures.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum studies: Chem panel, CBC, ESR, CRP, ANCA (if suspect vasculitic process), thyroid panel including TPO and thyroglobulin, am cortisol and ACTH, GQ1b antibodies (Bickerstaff encephalitis, rhomboencephalitis), celiac antibody panel, paraneoplastic and autoimmune encephalitis panels.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Rule out concurrent anemia/thrombocytopenia, which can present with severe headaches and confusion.</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild: No interference with function and symptoms not concerning to patient. Note: any cranial nerve problem</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">should be managed as moderate.</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="3" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">As above for aseptic meningitis suggest concurrent IV acyclovir until PCR results obtained and negative.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Trial of methylprednisolone 1-2 mg/kg/d.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If severe or progressing symptoms or oligoclonal bands present, consider pulse corticosteroids (methylprednisolone 1 g IV daily for 3-5 days) plus IVIG 2g/kg over 5 days (0.4 g/kg/d) or plasmapheresis.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Taper steroids following acute management over at least 4-6 weeks.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If positive for autoimmune encephalopathy or paraneoplastic antibody or limited or no improvement, consider Rituximab in consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient for G3-4</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: Some interference with ADLs, symptoms concerning to patient (i.e. pain but no weakness or gait</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">limitation).</p></td></tr><tr style="height:28pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: Limiting self-care and aids warranted.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.7. Demyelinating Diseases, including multiple sclerosis, transverse myelitis, ADEM, ON and NMO</p></td></tr><tr style="height:137pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurologic consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Ophthalmic or neuro-ophthalmic evaluation if ocular involvement</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI with contrast of brain, orbit, cervical, and thoracic spinal cord (tailor to exam finding).</span></p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Lumbar puncture with CSF analysis including autoimmune encephalitis panel and oligoclonal bands, CNS demyelinating disease antibodies (aquaporin 4 and myelin oligodendrocyte glycoprotein), viral PCRs especially JCV PCR to exclude progressive multifocal leukoencephalopathy.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum studies: B12, HIV, RPR, ANA, Ro/La, TSH, aquaporin-4 IgG, paraneoplastic panel or anti-HU and anti-CRMP5-CV2, thyroid panel including TPO and thyroglobulin, am cortisol and ACTH, paraneoplastic and autoimmune encephalitis panels.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for urinary retention, constipation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">EEG to evaluate for subclinical seizures.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Although less common, biopsy may provide definitive evidence of CNS demyelination.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7.0. Nervous System Toxicities</p></td></tr><tr style="height:22pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:26pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G1: <span class="s3">Asymptomatic or mild symptoms; clinical or diagnostic observations only</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Intervention not indicated.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue immunotherapy unless symptoms worsen or do not improve.</span></p></td></tr><tr style="height:51pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-top: 7pt;padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate symptoms; minimal, limiting age-appropriate instrumental ADL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Stop ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Start prednisone 1mg/kg daily and taper over 1 month.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Rule out infection.</span></p></td></tr><tr style="height:63pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Severe or medically significant symptoms but not immediately life- threatening; limiting self-care ADL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Non opioid management of neuropathic pain, for example, pregabalin, gabapentin, or duloxetine.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Admit patient for methylprednisolone pulse dosing 1g/d and consider IVIG<span class="s9">J </span>or plasmapheresis if no improvement or symptoms worsen after 3 days.<span class="s9">K</span></p></td></tr><tr style="height:63pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Neurology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">ICU level inpatient care.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Start methylprednisolone pulse dosing 1g/d and consider IVIG or plasmapheresis if no improvement or symptoms worsen after 3 days.</span><span class="s9">K</span></p></td></tr></table><p class="s11" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">I <span class="s12">The divergence from 1mg/kg in the setting of MG is due to the potential short-term exacerbation of MG with high-dose steroid.</span></p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">J <span class="s12">IVIG 2g/kg, administered in divided doses per package insert.</span></p><p class="s11" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">K <span class="s12">Plasmapheresis immediately after IVIG will remove immunoglobulin.</span></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.1. Hemolytic Anemia</p></td></tr><tr style="height:187pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">History and physical examination (with special consideration of history of new drugs, insect, spider, or snake bites)</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Blood chemistry, CBC with evidence of anemia, macrocytosis, evidence of hemolysis on peripheral smear. LDH, haptoglobin, bilirubin, reticulocyte count, free hemoglobin</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">DIC panel which could include PT or INR or PTT, and infectious causes</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Autoimmune serology</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">PNH screening</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Direct and indirect bilirubin, direct agglutinin test, and if no obvious cause, bone marrow analysis, cytogenetic analysis to evaluate MDS</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for viral/bacterial (mycoplasma etc.) causes of hemolysis studies</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Protein electrophoresis, cryoglobulin analysis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Workup for BM failure syndrome if refractory including B12, folate, copper, parvovirus, iron, thyroid, infection</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Glucose-6-phosphate dehydrogenase level</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation of common drug causes (ribavirin, rifampin, dapsone, interferon, cephalosporins, penicillins, NSAIDS, Quinine/quinidine, fludarabine, ciprofloxacin, lorazepam, and diclofenac)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Assessment of methemaglobinemia</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:24pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Hgb &lt; LLN to 10.0 g/dL; &lt; LLN to 6.2</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">mmol/L; &lt; LLN to 100 g/L</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi with close clinical follow-up and laboratory evaluation.</span></p></td></tr><tr style="height:26pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G2: <span class="s3">Hgb &lt; 10.0 to 8.0 g/dL; &lt; 6.2 to 4.9 mmol/L; &lt; 100 to 80g/L</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and strongly consider permanent discontinuation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer 0.5 to 1 mg/kg/d prednisone equivalents.</span></p></td></tr><tr style="height:100pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 16pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Hgb &lt; 8.0 g/dL; &lt; 4.9 mmol/L; &lt; 80 g/L; transfusion indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Should use clinical judgment and consider admitting the patient.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Prednisone 1-2 mg/kg/d (oral or IV equivalent depending on symptoms/speed of development).</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider RBC transfusion per existing guidelines. Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7 to 8 g/dL in stable, noncardiac inpatients).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Should offer patients supplementation with folic acid 1mg daily.</span></p></td></tr><tr style="height:100pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 30pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; urgent intervention indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">IV prednisone corticosteroids 1-2 mg/kg/d.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If no improvement on or if worsening on corticosteroids or severe symptoms on presentation, initiate other immunosuppressive drugs, such as rituximab, IVIG, cyclosporine, infliximab, MMF, or ATG.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">RBC transfusion per existing guidelines. Discuss with blood bank team prior to transfusions that a patient with possible ICPi SAE is in the hospital.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:24pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Monitor hemoglobin levels weekly until the steroid tapering process is complete. Thereafter, less frequent testing is needed.<span class="s9">18</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.2. Acquired TTP</p></td></tr><tr style="height:138pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">History with specific questions related to drug exposure (e.g. chemotherapy, sirolimus, tacrolimus, oxymorphone, antibiotics, and quinine)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Physical exam, peripheral smear to check for schistocytes</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">ADAMTS13 activity level and inhibitor titer</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">LDH, haptoglobin, reticulocyte count, bilirubin, urinalysis to rule out other causes</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Prothrombin time, activated partial thromboplastin time, fibrinogen</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Blood group and antibody screen, direct antiglobulin test</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider CT or MRI brain, echocardiogram, electrocardiogram</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Cytomegalovirus serology</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Note: this disorder is usually associated with severe drop in platelets and hemolysis/anemia precipitously (microangiopathy)</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:50pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">The first step in the management of TTP is a high index of suspicion for the diagnosis and timely recognition. Hematology consult should immediately be called, as delay in identification is associated with increased mortality/morbidity.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Initially, the patient should be stabilized, and any critical organ dysfunction stabilized.</span></p></td></tr><tr style="height:49pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Evidence of RBC destruction (schistocytosis) without anemia, renal insufficiency, or thrombocytopenia</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">clinically</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#F1F1F1"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits, noting that there is currently no data to recommend restarting ICPi therapy.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer 0.5 to 1 mg/kg/d prednisone.</span></p></td></tr><tr style="height:48pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Evidence of RBC destruction (schistocytosis) without clinical consequence with G2 anemia and</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">thrombocytopenia</p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Laboratory findings with clinical consequences (G3 thrombocytopenia,</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">anemia, renal insufficiency &gt; 2)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits, noting that there is currently no data to recommend restarting ICPi therapy.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">In conjunction with hematology, initiate therapeutic PEX according to existing guidelines with further PEX dependent on clinical progress.</span><span class="s9">19-22</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer methylprednisolone 1 g IV daily for 3 days, with the first dose typically administered immediately after the first PEX. For patient who has an initial platelet count response, discontinue PEX.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">May offer rituximab</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider caplacizumab if ADAMTS13 activity level is &lt; 10 IU/dL or &lt; 10% of normal, with an inhibitor or elevated anti-ADAMTS13 IgG.</span><span class="s9">19</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If no exacerbation within 3-5 days after stopping PEX, taper steroids over 2-3 weeks, complete course of rituximab (if receiving) and discontinue caplacizumab (if receiving).</span><span class="s9">20</span></p></td></tr><tr style="height:99pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure)</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.3. HUS</p></td></tr><tr style="height:213pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">History and physical examination (special consideration for new history of high-risk drugs, hypertension, or cardiac causes)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CBC with indices</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Blood smear morphology. Note that the presence of schistocytes on smear is critical for diagnosis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum creatinine</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">ADAMTS13 (to rule out TTP)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Homocysteine or MMA</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Complement testing C3, C4, CH50 (complement inhibitory antibodies for suspected familial)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluate reticulocyte count and MCV</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation of infectious cause including screening for viral EBV, CMV, HHV6</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for nutritional causes of macrocytosis (B12 and folate)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Pancreatic enzymes</span></p><p class="s3" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Evaluation for diarrheal causes, shiga toxin, <i>Escherichia coli </i>0157</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Direct antibody test (Coombs test), haptoglobin, LDH, and other etiologies of anemia</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for common drugs causing hemolysis (tacrolimus, cyclosporine, sirolimus, etc.)</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for neurologic changes (alteration in consciousness, concurrent confusion, seizures, pyramidal syndrome, and extrapyramidal syndrome with hypertonia)</span><span class="s9">23</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:49pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1-2: <span class="s3">Evidence of RBC destruction (schistocytosis) without clinical consequences of anemia,</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">thrombocytopenia grade 2</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-top: 11pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi with close clinical follow-up and laboratory evaluation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Supportive care</span></p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Laboratory findings with clinical consequences (e.g., renal insufficiency</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">and petechiae)</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#BEBEBE"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Begin therapy with eculizumab (anti-C5 antibody)<span class="s9">L </span>900mg weekly × 4 doses, 1200mg week 5, then 1200mg every two weeks.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Red blood transfusion according to existing guidelines.</span></p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences, (e.g., CNS thrombosis or embolism or renal</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">failure)</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.4. Aplastic Anemia</p></td></tr><tr style="height:151pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">History and physical examination (close attention to medications, exposure to radiation, toxins, recent viral infections)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CBC, smear, and reticulocyte count</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Viral studies including CMV, HHV6, EBV, parvovirus</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Nutritional assessments including B12, folate, iron, copper, ceruloplasmin, vitamin D</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Serum LDH and renal function</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Evaluation for infectious causes.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Identify marrow hypo/aplasia</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">BM biopsy and BM aspirate analysis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Peripheral blood analysis including neutrophil count, proportion of GPI-negative cells by flow for PNH</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Flow cytometry to evaluate loss of GPI-anchored proteins</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Type and screen patient for transfusions and notify blood bank that all transfusions need to be irradiated and filtered</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:60pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><b>G1: </b>Mild: &gt; 0.5 PMNs × 10<span class="s9">9</span>/L</p><p class="s3" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">hypocellular marrow, with marrow cellularity &lt; 25%, Peripheral platelet count &gt; 20,000, reticulocyte count &gt;</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,000</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 5pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi, provide growth factor support and close clinical follow-up and laboratory evaluation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Supportive transfusions as per local guidelines.</span></p></td></tr><tr style="height:63pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-top: 7pt;padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: Hypocellular marrow &lt; 25% and two of the following ANC &lt; 500, peripheral platelet &lt; 20,000 and reticulocyte &lt;2 0,000</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and provide growth factor support and close clinical laboratory evaluations daily.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer horse ATG plus cyclosporine.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Supportive transfusions as per local guidelines. All blood products should be irradiated and filtered.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">HLA typing and evaluation for bone marrow transplantation if patient is a candidate</span></p></td></tr><tr style="height:63pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: ANC &lt; 200, platelet count &lt; 20,000, reticulocyte count of &lt; 20,000, plus hypocellular marrow &lt; 25%.</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">As per G2</span></p><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Hold ICPi and monitor weekly for improvement. If not resolved, discontinue treatment until AE has reverted to G1.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If no response, repeat immunosuppression with rabbit ATG plus cyclosporine, cyclophosphamide.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">For refractory patients consider eltrombopag plus supportive care.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.5. Lymphopenia</p></td></tr><tr style="height:87pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">History (special attention to nutritional status and for lymphocyte depleting therapy such as fludarabine, ATG, steroids, cytotoxic chemotherapy, radiation exposure, etc. as well as history of autoimmune disease, family history of autoimmune disease)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Physical exam with special attention to spleen size</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CBC with differential, peripheral smear, and reticulocyte count</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CXR for evaluation of presence of thymoma</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Bacterial cultures and evaluation for infection (fungal, bacterial, viral - specifically CMV or HIV)</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:74pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">All Grades</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: justify;"><span class="s6">  </span><span class="s3">No specific action is required for lymphopenia G1-G3 and ICPi therapy should be continued.</span></p><p class="s3" style="padding-left: 41pt;padding-right: 34pt;text-indent: -18pt;text-align: justify;"><span class="s5"></span><span class="s6">  </span>For G4 (&lt; 250 PB lymphocyte count), continue ICPi therapy and initiate <i>Mycobacterium avium </i>complex prophylaxis and <i>Pneumocystis jirovecii </i>prophylaxis, CMV screening. HIV and hepatitis screening if not already done.</p><p class="s5" style="padding-left: 41pt;padding-right: 46pt;text-indent: -18pt;line-height: 12pt;text-align: justify;"><span class="s6">  </span><span class="s3">May consider EBV testing if evidence of lymphadenopathy or hepatitis, fevers, hemolysis occur c/w lymphoproliferative disease occurs.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.6. ITP</p></td></tr><tr style="height:125pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">History and physical examination (special attention for history of viral illness and lymphocyte depleting therapy such as fludarabine, ATG, steroids, cytotoxic therapy)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">FH of autoimmunity or personal history of autoimmune disease</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CBC, peripheral blood smear, reticulocyte count</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Bone marrow evaluation only if abnormalities in the above testing results and further investigation is necessary for a diagnosis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients with newly diagnosed ITP should undergo testing for HIV, HCV, HBV, and </span><span class="s8">H. pylori</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Direct antigen test should be checked to rule out concurrent Evan’s syndrome</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Nutritional evaluation</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">BM evaluation if other cell lines affected and concern for aplastic anemia</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:13pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">G1: <span class="s3">Platelet count 75 to &lt; 100/µL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi with close clinical follow-up and laboratory evaluation.</span></p></td></tr><tr style="height:50pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Platelet count 50 to &lt; 75/ µL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi but monitor for improvement. If not resolved, interrupt treatment until AE has reverted to G1.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer prednisone 1 mg/kg per day (dosage range, 0.5–2 mg/kg per day) orally for 4 weeks followed by taper over 4-6 weeks to the lowest effective dose.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">IVIG may be used in conjunction with corticosteroids if a more rapid increase in platelet count is required.</span></p></td></tr><tr style="height:42pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 3pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Platelet count 25 to &lt; 50/ µL</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">As per G2.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider as alternative to prednisone, dexamethasone 40mg daily for four days.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">If IVIG is used, the dose should initially be 1 g/kg as a one-time dose.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If previous treatment with corticosteroids and/or, IVIG, has been unsuccessful, subsequent treatment may include rituximab, thrombopoietin receptor agonists, or more potent immunosuppression.</span></p><p class="s8" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s3">(</span>From American Society of Hematology guideline on immune thrombocytopenia<span class="s17">24 </span>– consult for further details)</p></td></tr><tr style="height:45pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 4pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Platelet count &lt; 25/µL</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.0. Hematologic Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">8.7. Acquired Hemophilia A</p></td></tr><tr style="height:87pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hematology consult</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Full blood count to assess platelet number, fibrinogen, PT, PTT, INR. The typical finding in patients with acquired hemophilia A is a prolonged aPTT with a normal PT.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">MRI, CT, and ultrasonography may be indicated to localize, quantify, and serially monitor the location and response of bleeding.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Medication review to assess for alternative causes</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Determination of Bethesda unit level of inhibitor</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:51pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 7pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild: 5-40% of normal factor activity in blood; 0.05-0.4 IU/mL of whole blood</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administer 0.5 to 1 mg/kg/d prednisone.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Transfusion support as required.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Treatment of bleeding disorders with hematology consult.</span></p></td></tr><tr style="height:111pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 25pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Moderate: 1-5% of normal factor activity in blood; 0.01-0.05 IU/mL of whole blood</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discuss resumption with patient only after taking into account the risks and benefits.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administration of factor replacement (choice based on BU of titer).</span></p><p class="s3" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Administer 1 mg/kg/d prednisone ± rituximab (dose 375mg/m<span class="s9">2 </span>weekly × 4 weeks) and/or cyclophosphamide (dose 1-2mg/kg/d). Choice of rituximab versus cyclophosphamide is patient specific and should be done with assistance of hematology consult. Prednisone, rituximab, and cyclophosphamide should be given for at least 5 weeks.</p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Factors should be provided to increase level during bleeding episodes, with choice of factor based on presence or absence of inhibitor.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Transfusion support as required for bleeding.</span></p></td></tr><tr style="height:112pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3-4: <span class="s3">Severe: &lt; 1% of normal factor activity in blood; &lt; 0.01 IU/mL of whole blood</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Administration of factor replacement, choice based on BU level of inhibitor.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Bypassing agents may be used (Factor VII FEIBA). Caution should be taken in elderly patients and those with CAD.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Prednisone corticosteroids 1-2 mg/kg/d (oral or IV depending on symptoms) ± rituximab (dose 375mg/m<span class="s9">2 </span>weekly × 4 weeks) and/or cyclophosphamide (dose 1-2mg/kg/d).</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Transfusion support as required for bleeding.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">If worsening or no improvement add cyclosporine or immunosuppression or immunoadsorption.</span></p></td></tr><tr style="height:36pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Acquired hemophilia A requires special clinical and laboratory expertise. Consult and/or transfer to a specialist center is often appropriate. If consultation with or transfer to a hemophilia center is not immediately possible, then investigation and treatment should be initiated while a liaison is being established.<span class="s9">25</span></p></td></tr></table><p class="s11" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">L <span class="s12">Patients should be immunized with a meningococcal vaccine at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risks of developing a meningococcal infection.</span></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.0. Cardiovascular Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.1. Myocarditis, Pericarditis, Arrhythmias, Impaired Ventricular Function with Heart Failure, and Vasculitis</p></td></tr><tr style="height:161pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">ECG</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">Troponin, and CPK to rule out concurrent myositis, especially in patients treated with combination immune therapies. Alternative reasons for elevation should be ruled out.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">If elevated, troponin should be serially monitored. With elevated troponin, be aware of the potential for triple M irAEs – myositis, myasthenia, and myocarditis – and refer to subspecialties.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">BNP</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Echocardiogram</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Chest X-ray</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional testing to be guided by cardiology and may include:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Stress test</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Cardiac catheterization</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Cardiac MRI</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Abnormal cardiac biomarker testing without symptoms and with no ECG</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">abnormalities</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="4" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">All grades warrant workup and intervention given the potential for cardiac compromise.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>Hold ICPi for G1 elevated troponin<span class="s9">M </span>and recheck troponin 6 hours later. May consider resuming once normalized or if believed not to be related to ICPi.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and discontinue for ≥G2.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">For patients with grade ≥2, early (i.e. within 24 hours) initiation of high-dose corticosteroids (1-2 mg/kg/d of prednisone, oral or IV depending on symptoms) should be considered as it is likely to be beneficial without adverse effects.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient, cardiology consultation.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Management of cardiac symptoms according to ACC/AHA guidelines and with guidance from cardiology.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Immediate transfer to a coronary care unit should be considered for patients with elevated troponin or conduction abnormalities.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">For new conduction delay, consider a pacemaker.</span></p><p class="s3" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s5"></span><span class="s6">  </span>In patients without an immediate response to high-dose corticosteroids, consider early institution of cardiac transplant rejection doses of corticosteroids (methylprednisolone 1 g every day) and the addition of either mycophenolate, infliximab, or anti-thymocyte globulin.<span class="s9">26 </span>Consider abatacept (costimulatory molecule</p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">blockade) or alemtuzumab (CD52 blockade) as additional immunosuppression in life threatening cases.<span class="s9">27,28</span></p></td></tr><tr style="height:37pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Abnormal cardiac biomarker testing</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">with mild symptoms or new ECG abnormalities without conduction delay</p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Abnormal cardiac biomarker testing with either moderate symptoms or new</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">conduction delay</p></td></tr><tr style="height:88pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 8pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Moderate to severe decompensation, IV medication or intervention required, life threatening conditions</span></p></td></tr><tr style="height:36pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s8" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Qualifying Statement: <span class="s3">Treatment recommendations are based on anecdotal evidence and the life-threatening nature of cardiovascular complications. Holding</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">checkpoint inhibitor therapy is recommended for all grades of complications. The appropriateness of rechallenging remains unknown. Note that infliximab has been associated with heart failure and is contraindicated at high doses (i.e. &gt; 5mg/kg) in patients with moderate-severe heart failure.<span class="s9">29,30</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.0. Cardiovascular Toxicities</p></td></tr><tr style="height:22pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.2. Venous Thromboembolism</p></td></tr><tr style="height:112pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Evaluation of signs and symptoms of PE or DVT may include:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Clinical prediction rule to stratify patients with suspected VTE</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Venous ultrasound for suspected DVT</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">CTPA for suspected PE</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Can also consider D-dimer for low-risk patients based on risk stratification by clinical prediction rule for DVT/PE when CT or Doppler not available or appropriate</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">V/Q scan is also an option when CTPA is not appropriate</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider other testing, including ECG, chest radiography, BNP and troponin levels, and ABG</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Venous thrombosis (e.g., superficial thrombosis)</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Warm compress.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Clinical surveillance.</span></p></td></tr><tr style="height:99pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Venous thrombosis (e.g., uncomplicated deep vein thrombosis), medical intervention indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Management according to CHEST, ACC, and/or AHA guidelines and consider consult from cardiology or other relevant specialties.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">LMWH, VKA, dabigatran, rivaroxaban, apixaban, or edoxaban for initial anticoagulation treatment. For long- term anticoagulation, LMWH, edoxaban, rivaroxaban, or apixaban for at least 6 months are preferred over VKAs because of improved efficacy.</span><span class="s9">31,32</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">IV heparin is an acceptable alternative for initial use and oral anticoagulants are acceptable for the long term.</span></p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Venous thrombosis (e.g., uncomplicated pulmonary embolism),</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">urgent medical intervention indicated</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and may reintroduce after risk/benefit are considered.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2 anticoagulation recommendations.</span></p></td></tr><tr style="height:75pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; hemodynamic or neurologic instability; organ damage; loss of extremity(ies)</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi and may reintroduce after risk/benefit are considered.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Admit patient and management according to CHEST, ACC, and/or AHA guidelines and with guidance from cardiology.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Respiratory and hemodynamic support.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Follow G2 anticoagulation recommendations with further clinical management as indicated based on symptoms.</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">9.0. Cardiovascular Toxicities</p></td></tr><tr style="height:110pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">VTE prophylaxis in high-risk outpatients with cancer (Khorana score of 2 or higher prior to starting a new systemic regimen) may be offered thromboprophylaxis with apixaban, rivaroxaban, or LMWH provided there are no significant risk factors for bleeding and no drug interactions, as per ASCO VTE guideline.</span><span class="s9">31</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Although it may be impossible to determine the etiology of thromboembolic disease in patients with advanced cancer and the role, if any, that ICPi treatment plays, it is reasonable to remove the potential inciting agents given the severity and life-threatening potential of grade 4 complications. Clinicians are to use clinical judgment and take into account the risks and benefits when deciding whether to discontinue ICPi treatment.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Anticoagulant therapy duration should continue while on immunotherapy and consideration be given to continuing for an additional 6 months following completion of immunotherapy.</span><span class="s9">31</span></p></td></tr></table><p class="s11" style="padding-left: 6pt;text-indent: 0pt;line-height: 119%;text-align: left;">M <span class="s12">According to CTCAE v5.0, G1 elevated troponin is defined as levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer.</span></p><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.0. Ocular Toxicities</p></td></tr><tr style="height:199pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Evaluation, under the guidance of ophthalmology:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Check vision in each eye separately</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Color vision</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Red reflex</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Pupil size, shape, and reactivity</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Fundoscopic examination</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Inspection of anterior part of eye with penlight</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Slight lamp exam</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Eye pressure</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Need to rule out myasthenia gravis</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Prior Conditions</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Exclude patients with history of active uveitis</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">History of recurrent uveitis requiring systemic immunosuppression or continuous local therapy</span></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 5pt;padding-right: 11pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Clinicians should be aware that ocular irAEs commonly accompany other organ irAEs, and there should be a high level of clinical suspicion, as symptoms may not always be associated with severity. Patients with all grades of ocular symptoms should be referred to ophthalmology.</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.1. Uveitis or Iritis</p></td></tr><tr style="height:24pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation<span class="s3">: As per 10.0</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Ophthalmology consult should be universal for the symptoms described in 10.0.</p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Anterior uveitis with trace cells</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Prompt referral to ophthalmology (usually within 1 week)</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Artificial tears.</span></p></td></tr><tr style="height:99pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Anterior uveitis with 1+ or 2+ cells</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily until after ophthalmology consult.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent ophthalmology referral.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Topical corticosteroids (e.g. 1% prednisolone acetate suspension), cycloplegic agents (e.g. atropine), systemic corticosteroids.</span><span class="s9">33</span></p><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">May resume ICPi treatment once off systemic steroids if patient has only ocular irAE, once corticosteroids are reduced to ≤ 10mg prednisone equivalent. Continued topical/ocular steroids are permitted when resuming therapy to manage and minimize local toxicity.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Retreat after return to ≤ G1.</span></p></td></tr><tr style="height:63pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Anterior uveitis with 3+ or greater cells; intermediate posterior or pan- uveitis</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent ophthalmology referral.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Systemic corticosteroids and intravitreal or periocular or topical corticosteroids.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Methotrexate may be used in patients who respond poorly to systemic corticosteroids or those with severe</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">sight‐threatening inflammation.<span class="s9">33</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.0. Ocular Toxicities</p></td></tr><tr style="height:50pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">Best corrected visual acuity of 20/200 or worse in the affected eye</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Emergent ophthalmology referral.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Systemic corticosteroids - prednisone 1-2mg/kg/d or methylprednisolone 0.8-1.6mg/kg/d and intravitreal or periocular or topical corticosteroids per ophthalmologist opinion.</span></p></td></tr><tr style="height:12pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Additional Considerations: <span class="s3">Consider use of infliximab, other TNFα blockers, or IVIG in cases that are severe and refractory to standard treatment.</span><span class="s9">34,35</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10.2. Episcleritis</p></td></tr><tr style="height:13pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Workup and Evaluation: <span class="s3">As per 10.0</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Asymptomatic</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Prompt ophthalmology referral (usually within 1 week).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Artificial tears.</span></p></td></tr><tr style="height:50pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p style="padding-top: 7pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G2: <span class="s3">Vision 20/40 or better</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi therapy temporarily until after ophthalmology consult.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent ophthalmology referral.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Topical corticosteroids (e.g. 1% prednisolone acetate suspension), cycloplegic agents (e.g. atropine), systemic corticosteroids.</span><span class="s9">33</span></p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Symptomatic and vision worse than 20/40</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Urgent ophthalmology referral.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Systemic corticosteroids and topical corticosteroids with cycloplegic agents.</span></p></td></tr><tr style="height:38pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p style="padding-top: 1pt;text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G4: <span class="s3">20/200 or worse</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Emergent ophthalmology referral.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Systemic corticosteroids and topical corticosteroids with cycloplegic agents.</span></p></td></tr><tr style="height:12pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Additional Considerations: <span class="s3">Consider use of infliximab or other TNFα blockers in cases that are severe and refractory to standard treatment.</span><span class="s9">34,35</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.0. Systemic Toxicities</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.1. Infusion-Related Reactions (IRRs)</p></td></tr><tr style="height:50pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Workup and Evaluation:</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Physical exam including vital signs</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Pulse oximetry</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">ECG if chest pain or sustained tachycardia</span></p></td></tr><tr style="height:23pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grading</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Management</p></td></tr><tr style="height:36pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G1: <span class="s3">Mild transient reaction; infusion interruption not indicated; intervention</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">not indicated</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#F1F1F1"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Continue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">May consider premedication with acetaminophen and an antihistamine for subsequent infusions.</span></p></td></tr><tr style="height:50pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G2: <span class="s3">Therapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medication indicated for ≤ 24 hours</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#D9D9D9"><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider holding ICPi temporarily and/or reducing the rate of infusion to 50% (or per institutional guidelines).</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Offer symptomatic treatment with antihistamines, NSAIDs, opioids, and IV fluids as clinically appropriate.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Offer prophylactic acetaminophen and an antihistamine per institution guidelines for subsequent infusions.</span></p></td></tr><tr style="height:72pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">G3: <span class="s3">Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated</span></p><p class="s3" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">for other clinical sequelae</p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#BEBEBE"><p class="s5" style="padding-top: 4pt;padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hold ICPi temporarily and consider resuming, at an infusion rate of 50% (or per institutional guidelines), once</span></p><p class="s3" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">return to ≤ G1.</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Offer symptomatic treatment with antihistamines, NSAIDs, opioids, and IV fluids as clinically appropriate.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Consider antihistamines and corticosteroid medications intravenously.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Hospitalization for other clinical sequelae.</span></p></td></tr><tr style="height:26pt"><td style="width:193pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s2" style="padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;line-height: 12pt;text-align: left;">G4: <span class="s3">Life-threatening consequences; urgent intervention indicated</span></p></td><td style="width:527pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#A6A6A6"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Permanently discontinue ICPi.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">ICU level inpatient care.</span></p></td></tr><tr style="height:36pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Additional Considerations:</p><p class="s3" style="padding-left: 5pt;padding-right: 14pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Clinicians may consider switching to an alternate agent in the therapeutic class upon rechallenge or consider rechallenging with the offending immunotherapy agent through a desensitization procedure under the supervision of an allergist.</p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.0. Steroids</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.1. Pretreatment Considerations</p></td></tr><tr style="height:99pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Baseline workup to include viral hepatitis B and C serology and consideration for latent or active TB test. In patients with pre-existing HIV, testing HIV viral load and CD4 count would be appropriate.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients with preexisting comorbid conditions, such as DM, hypertension, HF, cataract, glaucoma, infection, or osteoporosis, should have their condition optimally managed prior to commencing steroids.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Ideal steroid dosing and duration is individualized and can vary by patient, oncologic agents, and type of irAE. Please refer to each individual irAE section for more detail.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">The lowest dose of steroids should be used for the shortest duration of time needed to achieve treatment goals and control deleterious effects of irAE, as the risk of toxicity with steroids is generally dose- and duration-dependent.</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.2. Prevention of Opportunistic Infection</p></td></tr><tr style="height:62pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Use of prophylaxis for an opportunistic infection with PJP may be considered once a patient has received a prednisone equivalent of ≥ 20 mg/d for 4 or more weeks or &gt; 30mg for 3 weeks or more. Physicians may proceed according to institutional guidelines.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">The role of prophylactic fluconazole with prolonged steroid use (&gt; 12 weeks) remains unclear and physicians should proceed according to institutional guidelines.</span><span class="s9">36</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Use of prophylaxis against herpes zoster reactivation may be offered to patients who have had zoster before and will be receiving corticosteroids.</span><span class="s9">37</span></p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.3. Monitoring for Acute or Short-Term and Long-Term Adverse Effects</p></td></tr><tr style="height:254pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients should be routinely asked about adverse effects related to glucocorticoids. During treatment with glucocorticoids and depending upon individual risk factors such as dose and duration of glucocorticoid usage, other medications being used, and comorbidities, particular attention should be given to the following acute/short-term and long-term adverse effects:</span></p><p class="s3" style="padding-left: 77pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Acute/short-term AEs</p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Increased vulnerability to infection</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Insomnia</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Anxiety</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Diabetes or glucose intolerance</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Hypertension</span></p><p class="s7" style="padding-left: 77pt;padding-right: 517pt;text-indent: 18pt;text-align: left;">o <span class="s3">Cutaneous changes Long-term AEs</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Bone loss (osteopenia and osteoporosis) and fractures</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Cataracts or glaucoma</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Steroid myopathy</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Relative adrenal insufficiency</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Psychiatric disturbance</span></p><p class="s7" style="padding-left: 95pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="s3">Gastric or duodenal ulcers</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">GI prophylaxis with PPI or H2 antagonist is recommended.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">To limit steroid-induced bone loss, patient should receive adequate calcium (dietary or supplementation), vitamin D, and weight-bearing exercise should</span></p><p class="s3" style="padding-left: 41pt;padding-right: 7pt;text-indent: 0pt;line-height: 12pt;text-align: left;">be encouraged when feasible. Bone-modifying agents may be offered to patients on steroids for &gt; 3 months and are recommended for all patients with pre-existing osteoporosis. Patients with or at risk for osteoporosis who have long-term survival potential should undergo bone mineral density testing.<span class="s9">38</span></p></td></tr></table><table style="border-collapse:collapse;margin-left:6.25pt" cellspacing="0"><tr style="height:26pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#002456"><p class="s4" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.0. Steroids</p></td></tr><tr style="height:23pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" bgcolor="#DBE4F0"><p class="s2" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.4. Tapering of Steroids</p></td></tr><tr style="height:235pt"><td style="width:720pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6"> </span><span class="s3">The length of steroid-taper should occur according to the type and severity of irAE, the initial steroid dose, and individual patient responses rather than other prespecified criteria.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Steroid taper should occur slowly, generally over 4-6 weeks.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Regular clinical evaluation should occur during steroid tapering as there is a risk of irAE rebound or recurrence.</span></p><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">In general, oral steroid tapering is recommended to occur over 4-6 weeks, with a reduction in prednisone or prednisolone of 10mg every 3-7 days (as irAE allows) until the dose is 10mg/d, then reduce by 5mg every 3-7 days for patients who respond quickly to steroids. For those who have received steroids for several weeks, tapering may be more prolonged.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">In general, for patients that require IV steroids, tapering is recommended to occur over 4 weeks or longer. The initial IV conversion from methylprednisolone if ≥ 1mg/kg/d would be to oral prednisone 1mg/kg/d at minimum and then taper as above.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">Longer steroid tapers (&gt; 4-6 weeks) may be required for complete resolution or to avoid recurrence or rebound of irAE events.</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Patients should be monitored for the symptoms of adrenal insufficiency after prolonged exogenous steroids</span></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;"><span class="s6">  </span><span class="s3">Stress doses may be needed in the event of illness, injury, and surgery</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">Option when ready to drop below 5 mg of prednisone or 0.5 mg of dexamethasone after a longer course with concern for iatrogenic adrenal insufficiency, is to transition to hydrocortisone at physiologic dosing (10 mg in the morning, 5 mg in the afternoon). This allows for faster recovery of the HPA axis because it restores diurnal patterns.</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><span class="s6">  </span><span class="s3">If indicated to control disease, a simultaneous slow, low dose taper of the long-acting steroid can be given (for example decreasing by 1 mg prednisone per week).</span></p><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s6">  </span><span class="s3">HPA axis function can be tested 24 hours from last oral hydrocortisone (skip PM dose, hold AM dose for labs) - measured AM cortisol and ACTH will reflect endogenous function. Ambiguous results can be clarified with an ACTH stimulation test similarly prepared for.</span></p></td></tr></table><p class="toc">&nbsp;</p><div class="toc"><a class="toc0" href="2021-ICPi-Summary-of-Recs-Table_files/part1.htm">Abbreviations.</a><a class="toc0" href="2021-ICPi-Summary-of-Recs-Table_files/part2.htm">References.</a></div><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="2021-ICPi-Summary-of-Recs-Table_files/part1.htm">Next &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
